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Peripheral arterial disease (PAD), which affects approximately 10 million
Americans, is characterized by atherosclerosis of the non-coronary arteries. PAD
produces a progressive accumulation of ischemic injury to the limbs that is reflected in a
gradual worsening in the myofiber morphology and oxidative damage in the
gastrocnemius muscle. In this study, we evaluated the hypothesis that quantitative
morphological and biochemical parameters of gastrocnemius myofibers change in a
consistent manner during the progression of PAD, provide an objective grading of muscle
degeneration in the ischemic limb, and correlate to clinical stage of PAD. Myofiber
morphometrics were determined precisely with mathematical equations that incorporated
multiple, objectively defined parameters including fiber density, roundness, minor and
major axes, and solidity. Oxidatively altered proteins (hydrazide-reactive carbonyls)
labeled with mechanisms-based molecular biomarkers were imaged with quantitative
fluorescence microscopy and were used to measure oxidative damage in the muscle. A
discriminant model was developed based on morphometric and oxidative stress
parameters that accurately identified control (85.7% accuracy), claudicating (78.9%
accuracy), and critical limb ischemia (85.0% accuracy) patients, with an overall

classification accuracy of 83.3% using a cross-validation procedure. We have established
that there are consistent and quantifiable changes in myofiber morphology and
biochemistry that reflect the progression of PAD muscle degeneration and offer the
possibility of an objective index for grading severity of disease within clinical
classifications, i.e., Fontaine Stages.
Further, we evaluated the use of Raman scattering spectral biomarkers to
characterize altered muscle biochemistry in PAD patients and correlate patient blood
flow (ABI) with key Raman spectral bands. A partial least squares regression model,
based on the Raman spectra, was able to predict patient ABIs with a correlation
coefficient of 0.85 using a full cross-validation. When using the first three partial least
squares factor scores in combination with linear discriminant analysis, the discriminant
model was able to correctly classify control, claudicating, and critical limb ischemia
patients with 100% accuracy, using a full cross-validation procedure. In this study, we
have demonstrated that Raman spectroscopy can be a powerful bioanalytical tool that is
capable of detecting and correlating biochemical composition with patient ABIs and
discriminating PAD clinical diagnosis.

iv
ACKNOWLEDGMENTS
I would like to take this opportunity to acknowledge and thank those who have
been part of my journey in achieving my Doctoral degree. First and foremost I am
extremely grateful to my sweet wife and family for their enduring love and support in
completing my Doctorate. I thank my wife for all of her hard work, for supporting our
family and taking care of our kids, while I was doing homework or spending late nights
in the lab. I thank my Mother and Father for their support and instilling within me a
desire to pursue my educational opportunities to the fullest extent.
It is with deep gratitude and appreciation that I acknowledge and thank my
advisor Dr. Jeyamkondan Subbiah from the Department of Biological Systems
Engineering, for believing in me and giving me the opportunity to work under him as a
graduate research assistant. In my view a mentor is a person who sees more talent and
ability within you, than you see in yourself, and helps bring it out of you. That is exactly
what Dr. Subbiah has done for me. Dr. Subbiah has encouraged me to be more
adventurous, to be a visionary, and to do things that I normally would not. He has taught
me to never give up, believe in myself, and have confidence. Dr. Subbiah has a “no
limits” attitude, is very positive and optimistic, and has been an incredible mentor and
example for me. In the past years as a graduate student under Dr. Subbiah, I have grown
so much as a person and in the areas of science and research. I am very pleased to be
associated with him and I appreciate his passion for people, science, and research.
I give special thanks to my committee members Dr. George Casale, Dr. Ashok
Samal, and Dr. Chris Bilder for their support, time, and effort in helping me with my
research. I thank Dr. Casale, from the Department of Surgery at the University of
Nebraska Medical Center, for the tremendous amount of time and effort in teaching me

v
about tissue biomarker labeling and fluorescence microscopy, in helping me with data
collection, and helping me with manuscript preparation. With deep gratitude I thank Dr.
Ashok Samal from the Department of Computer Science for his assistance in computer
vision and image processing techniques, and for his valuable advice throughout my
graduate program. I give my appreciation to Dr. Chris Bilder, from the Department of
Statistics, for his assistance in data analysis and providing feedback on how to improve
my research.
I would also like to acknowledge and give thanks to Dr. Iraklis Pipinos, a vascular
surgeon at the University of Nebraska Medical Center, who was instrumental in this
research by collecting muscle tissue biopsies, allowing me to observe surgeries, provided
me with great advice and insight throughout my work. I thank Dr. Pipinos for affording
me several opportunities to present this research at the medical center and for offering his
support and collaboration in our work.
I extend a special thanks to my good friend Abby Kelly who was instrumental in
helping me with data collection and image processing. It was a pleasure to work with
Abby; she is a very hard worker and I appreciate the time and support that she gave me. I
also give special thanks to Dimitrios Miserlis and Panagiotis Koutakis for all the time and
effort they put into helping me with data collection and for becoming my good friends. I
extend a special thanks to Govindarajan Konda Naganathan (K.N.) who has been like a
personal mentor to me. K.N. has provided tremendous support and friendship throughout
my time as a graduate student. I give thanks to K.N. for his willingness to help, and for
his example as an outstanding individual who constantly gives selfless service to others.

vi
I give thanks to Dr. Randy Wehling and Dr. Vicki Schlegel, professors in the
Department of Food Science and Technology, for their expert help in teaching me about
Raman and Fourier transform infrared spectroscopy. I give my sincere thanks to the
many anonymous veteran volunteers, who continue to serve their country in donating
muscle biopsies during surgery. Without their courage to donate muscle biopsies this
research to advance the field of diagnosis and treatment of peripheral arterial disease
would not be possible. Finally, I would like to record my sincere thanks to the faculty
and staff of the Department of Biological Systems Engineering in helping me to grow
personally as well as professionally and helping me to feel at home here at the University.

vii

Table of Contents
Chapter 1 : Introduction ...................................................................................................... 1
1.1

Background of Peripheral arterial disease (PAD) ................................................ 1

1.2

Significance of PAD............................................................................................. 2

1.2.1

Economic impact .......................................................................................... 3

1.2.2

Severity of PAD and Survival....................................................................... 4

1.3

Statement of the Problem ..................................................................................... 5

1.4

Objectives ............................................................................................................. 7

1.4.1

Specific objectives of this research are to: .................................................... 7

1.5

Dissertation Organization ..................................................................................... 8

1.6

References ............................................................................................................ 9

Chapter 2 : Literature Review ........................................................................................... 13
2.1

Diagnosis & Clinical manifestations .................................................................. 13

2.1.1

Risk Factors ................................................................................................ 13

2.1.2

Smoking ...................................................................................................... 14

2.1.3

Diabetes mellitus......................................................................................... 15

2.1.4

Age & Gender ............................................................................................. 16

2.1.5

Race............................................................................................................. 17

2.1.6

Ankle Brachial Index (ABI)........................................................................ 18

2.1.7

Claudication & Critical Limb Ischemia ...................................................... 23

2.1.8

Fontaine stages & Rutherford’s categories ................................................. 24

2.2

Muscle Morphology ........................................................................................... 26

2.2.1

Muscle Ultrastructure.................................................................................. 26

2.2.2

Contraction-Relaxation cycle of muscle ..................................................... 29

2.2.3

Morphology................................................................................................. 31

2.3

Oxidative damage ............................................................................................... 34

2.3.1

Mitochondria and the Electron Transport Chain (ETC) ............................. 34

2.3.2

Mitochondriopathy...................................................................................... 38

2.3.3

In vivo & In vitro evaluation of PAD mitochondria dysfunction ............... 39

2.3.4

Oxidatively altered proteins ........................................................................ 40

2.4

Vibrational Spectroscopy ................................................................................... 44

viii
2.4.1

Electromagnetic radiation ........................................................................... 44

2.4.2

Spectroscopy ............................................................................................... 45

2.4.3

Light Scattering........................................................................................... 46

2.4.4

Raman Spectroscopy................................................................................... 48

2.4.5

Raman active molecules vs. IR active molecules ....................................... 50

2.4.6

Biomedical applications of spectroscopy.................................................... 51

2.5

Summary ............................................................................................................ 56

2.6

References .......................................................................................................... 58

Chapter 3 : Morphometric Analysis of Gastrocnemius Muscle Biopsies from Patients
with Peripheral Arterial Disease: Objective Grading Of Muscle Degeneration ............... 70
3.1

Abstract .............................................................................................................. 71

3.2

Introduction ........................................................................................................ 73

3.3

Methods & Materials .......................................................................................... 74

3.3.1

Tissue Sample Collection ........................................................................... 74

3.3.2

Fluorescence Labeling of Tissue Sections .................................................. 75

3.3.3

Fluorescence Image Acquisition ................................................................. 76

3.3.4

Image Processing ........................................................................................ 76

3.3.5

Morphometric Measures ............................................................................. 77

3.3.6

Discriminant Model Development .............................................................. 79

3.4

Results ................................................................................................................ 80

3.5

Discussion .......................................................................................................... 84

3.6

References ........................................................................................................ 101

Chapter 4 : Carbonylated Proteins and Myofiber Morphometrics Characterize Muscle
Degeneration in Patients with Peripheral Arterial Disease ............................................. 105
4.1

Abstract ............................................................................................................ 106

4.2

Introduction ...................................................................................................... 107

4.3

Materials and Methods ..................................................................................... 109

4.3.1

Tissue Samples.......................................................................................... 109

4.3.2

Fluorescence Labeling of Tissue Sections ................................................ 109

4.3.3

Fluorescence Image Acquisition ............................................................... 112

4.3.4

Image Processing ...................................................................................... 112

ix
4.3.5

Heuristic rules to improve myofiber image segmentation ........................ 113

4.3.6

Oxidative Damage and Morphometric Measures ..................................... 115

4.3.7

Data Analysis ............................................................................................ 117

4.4

Results and Discussion ..................................................................................... 119

4.5

Conclusion........................................................................................................ 123

4.6

References ........................................................................................................ 137

Chapter 5 : Label Free Surface-Enhanced Raman Spectral Biomarkers Correlate With
PAD Patient ABIs And Characterize PAD Muscle Biochemical Alterations ................ 139
5.1

Abstract ............................................................................................................ 140

5.2

Introduction ...................................................................................................... 141

5.3

Materials and Methods ..................................................................................... 143

5.3.1

Tissue Samples.......................................................................................... 143

5.3.2

Surface Enhanced Raman Spectroscopy (SERS) ..................................... 143

5.3.3

Data preprocessing .................................................................................... 144

5.3.4

Model development .................................................................................. 145

5.4

Results .............................................................................................................. 146

5.4.1

Surface enhanced Raman spectroscopy .................................................... 146

5.4.2

Partial least squares regression and discriminant analysis ........................ 146

5.5

Discussion ........................................................................................................ 147

5.6

References ........................................................................................................ 160

Chapter 6 : Summary and Recommendations for future research .................................. 167
6.1

Summary .......................................................................................................... 167

6.1.1

Objective 1 – Morphometric analysis of PAD muscle ............................. 168

6.1.2

Objective 2 – Oxidative damage and morphometric analysis of PAD muscle
……………………………………………………………………………169

6.1.3

Objective 3 – Raman spectral analysis of PAD muscle ............................ 170

6.2

Recommendations for future research.............................................................. 171

6.3

References ........................................................................................................ 175

Chapter 7 : Appendices: .................................................................................................. 177
7.1

Example Myosin and Sarcolemma labeling protocol used in Chapter 3 ......... 177

7.2

Example protein carbonly labeling protocol used in Chapter 4. ...................... 181

x

List of Tables
Table 2.1. Fontaine stages and Rutherford categories are often used in research studies
to quantify stages and progression of PAD. Source: (Fontaine et al., 1954;
Rutherford et al., 1997) ................................................................................ 25
Table 3.1. Demographics of patients with peripheral arterial disease (PAD) and control
patients. ......................................................................................................... 98
Table 3.2. Combining models 1 & 2 training results, classification table. ...................... 99
Table 3.3. Combining models 1 & 2 validation results, classification table. ................. 100
Table 4.1. Demographics of patients with peripheral arterial disease (PAD) and control
patients. ....................................................................................................... 136
Table 4.2. Discriminant model classification table cross-validation results. ................ 136
Table 5.1. Demographics of patients with peripheral arterial disease and control patients.
.................................................................................................................... 158
Table 5.2. Patient classification with a discriminant model and cross validation results.
.................................................................................................................... 159

xi
List of Figures
Figure 1.1. Coexistence and distribution of three most prevalent forms of vascular
disease. Coronary heart disease (CHD), cerebrovascular disease (CVD), and
peripheral arterial disease (PAD). Modified from: (Bhatt et al., 2006) ......... 3
Figure 1.2. Mortality of patients presenting with peripheral arterial disease. IC –
intermittent claudication; CLI – critical limb ischemia. Courtesy of:
(Norgren et al., 2007) ..................................................................................... 5
Figure 2.1. Range of odds ratios of risk factors for developing symptomatic peripheral
arterial disease. Modified from: (Norgren et al., 2007) ............................... 14
Figure 2.2. Approximate magnitude of increase in risk of developing PAD based on
identified risk factors. Modified from: (Norgren et al., 2007) .................... 15
Figure 2.3. PAD prevalence increases as one gets older. PAD is more common among
men. Courtesy of (Criqui et al., 1985). ........................................................ 17
Figure 2.4. Ankle brachial index (ABI): Modified from: (Norgren et al., 2007) ........... 19
Figure 2.5 There is an inverse relationship between ABI and the odds of having a major
cardiovascular event. The lower the ABI the higher the odds of having a
myocardial infarction, stroke, or death. Courtisy of: (Mehler et al., 2003) . 21
Figure 2.6. Organization of mammalian skeletal muscle structure. Image courtesy of
(Silverthorn, 2004) ....................................................................................... 26
Figure 2.7. Ultrastructure of an individual myofiber made up of many myofibrils. Image
courtesy of (Silverthorn, 2004)..................................................................... 27
Figure 2.8. Micro-architecture of myofibrils and myofilaments. Image courtesy of
(Silverthorn, 2004) ....................................................................................... 28
Figure 2.9. Healthy, normal muscle morphology. ........................................................... 32

xii
Figure 2.10. Moderate myopathic myofibers from a PAD patient. ................................ 32
Figure 2.11. Severely myopathic myofibers from a PAD patient. .................................. 33
Figure 2.12. Within the mitochondria ATP synthesis is driven by the energy produced
via the electron flow along the electron transport chain and the generated
proton gradient. Image courtesy of (Nelson and Cox, 2004). ...................... 36
Figure 2.13. Reactive oxygen species can be produced at complexes I and III in the
electron transfer chain. Superoxide dismutase is an antioxidant enzyme that
helps render free radicals harmless. Image courtesy of (Nelson and Cox,
2004) ............................................................................................................. 37
Figure 2.14. A) Control and B) ischemic mouse muscle were labeled with fluorescent
biomarkers specific for HNE-protein adducts. Evidence of lipid
peroxidation is manifested by increased levels of 4-hydroxy-2-nonenal
(HNE) labeling, yielding a brighter image in the ischemic mouse muscle.
Image source: (Pipinos et al., 2008) ............................................................. 42
Figure 2.15. A & C present control and B & D present ischemic mouse muscle labeled
with antibodies against ATP synthase, where A & B are at a higher
magnification. The higher intensity labeling in B & D indicate higher
mitochondrial content in ischemic mouse muscle. E presents control and F
presents ischemic mouse muscle labeled with monoclonal antibodies specific
for manganese superoxide dismutase. The higher intensity in E indicates
higher levels of the dismutase in ischemic mouse muscle. Source: (Pipinos et
al., 2008) ....................................................................................................... 43
Figure 2.16. Electromagnetic spectrum. Image courtesy of (Pedrotti et al., 2007) ........ 45

xiii
Figure 2.17. Energy diagram depicting elastic Rayleigh scattering and Stokes and AntiStokes Raman scattering. (Sasic and Ozaki, 2010) ...................................... 49
Figure 2.18. Raman scattering (lower) and FTIR (upper) spectra of oleic acid methyl
ester, depict the selection rules of each spectroscopic method and their
complementary nature. Source: (McCreery, 2000) ...................................... 51
Figure 2.19. Raman spectra of A) normal artery, B) artery with lipid rich plaque, and C)
artery with calcified plaque. The bottom line in each spectra is the residual
between the Raman spectra and a fitted model. Source: (Buschman et al.,
2001) ............................................................................................................. 54
Figure 2.20. Raman spectral signature associated with mitochondrial activity. Source:
(Huang, 2004) ............................................................................................... 56
Figure 3.1. A) The sarcolemma labeling provided an outline of each myofiber. B) The
myosin labeling served as a confirmation that a given sarcolemma outline
encompassed a myofiber. C) The final binary segmented image contained
the geometry of each myofiber. Note that myofibers on the edge of the
image were removed, as accurate morphometric parameters could not be
extracted from only part of the myofibers. ................................................... 90
Figure 3.2. A) Normal muscle with polygonal shaped myofibers that are uniform in
shape and size, peripherally located nuclei and thin endomysium and
perimysium. B) A specimen of mildly damaged PAD muscle with evidence
of mild myofiber atrophy, the presence of rounded or angular atrophic
myofibers. C) A specimen of moderately damaged PAD muscle with
evidence of moderate myofiber atrophy, rounded or angular atrophic

xiv
myofibers, occasional internal nuclei, vacuolization and moderate
endomysial fibrosis. D) A specimen of moderately damaged PAD muscle
with evidence of severe myofiber atrophy and enlargement, angular,
polygonal or round myofibers, increased numbers of internal nuclei, and
moderate endomysial and perimysial fibrosis. ............................................. 92
Figure 3.3. Patient scores from Model 1 discriminating claudicating patients from CLI
patients, based on mophometric parameters of their gastrocnemius
myofibers. Claudicating patients closer to zero have myofiber morphology
that is approaching or is more similar to the myofiber morphology of CLI
patients. ......................................................................................................... 93
Figure 3.4. Means of standardized selected parameters for Model 1, used to
discriminate between critical limb ischemia (CLI) and Control/Claudicating
patients. ......................................................................................................... 94
Figure 3.5. Fiber density was defined as the area occupied by the myofibers divided by
the area occupied by the myofibers plus interstitial tissue. Panels A & D
display myosin images, with myofiber segmentation overlaid in green.
Panel B presents the fiber density (0.86) of a muscle tissue sample from a
control subject, while Panel E presents the fiber density (0.70) of a muscle
tissue sample from a patient with critical limb ischemia (CLI) and severe
myopathic changes. Panels C & F display sarcolemma image, with
myofiber segmentation overlaid in green. .................................................... 95
Figure 3.6. Binary images of segmented myofibers. A) Control. B) Critical limb
ischemia (CLI). C) Control middle 50% based on fiber area (M50%

xv
Solidity) and fitted convex hulls (red). D) CLI middle 50% based on fiber
area and fitted convex hulls (red). M50% CLI fibers exhibit higher variation
in solidity (i.e. more concavities) compared to M50% control fibers. Arrows
identify myofibers with reduced solidity. ..................................................... 96
Figure 3.7. Means of standardized selected parameters for Model 2, used to discriminate
between Controls and Claudicating patients. ............................................... 97
Figure 4.1. Protein carbonyl labeled image. High resolution tiled image (5376 × 6144
pixels) of ~1000 myofibers. Spatial calibration reference bar is 200 µm. 125
Figure 4.2. Myosin labeled image. High resolution tiled image (5376 × 6144 pixels) of
~1000 myofibers. Spatial calibration reference bar is 200 µm. ................. 126
Figure 4.3. Sarcolemma labeled image. High resolution tiled image (5376 × 6144 pixels)
of ~1000 myofibers. Spatial calibration reference bar is 200 µm. ............. 127
Figure 4.4. Myofiber nuclei labeled image. High resolution tiled image (5376 × 6144
pixels) of nuclei from ~1000 myofibers. Spatial calibration reference bar is
200 µm. ....................................................................................................... 128
Figure 4.5. Binary myofiber segmentation image. High resolution tiled image (5376 ×
6144 pixels) of ~1000 segmented myofibers. ............................................ 129
Figure 4.6. Flow chart of myofiber segmentation process using both myosin labeled
image and sarcolemma labeled image. ....................................................... 130
Figure 4.7. Examples of myofiber segmentation errors and heuristic rules used to
improve automated myofiber segmentation. Green circled areas represent the
correct segmentation and the fibers that were used to build the final
segmented image. Red circled areas represent segmentation errors that were

xvi
recognized by the heuristic algorithm and therefore removed from the final
segmented image. 1) Not a myofiber check, 2) Split narrow myofibers
check, 3) Joint myofibers check, 4) Poor segmentation due to non-uniform
labeling check, 5) Preserve shape of small fibers during erosion and dilation
check. .......................................................................................................... 132
Figure 4.8. Micro-fiber clustering or group atrophy events were identified using a
density based clustering routine and statistical measures were acquired to
quantify clustering of small degenerating myofibers. ................................ 133
Figure 4.9. Means of standardized selected variables for Model 1, used to discriminate
between critical limb ischemia (CLI) patients from Control and Claudicating
patients. ....................................................................................................... 134
Figure 4.10. Means of standardized selected parameters for Model 2, used to
discriminate between Controls and Claudicating patients.......................... 135
Figure 5.1. A) Raman spectra were baseline corrected using a 5th order polynomial with
the Vancouver Raman Algorithm. B) The extracted Raman signal after
baseline correction. ..................................................................................... 152
Figure 5.2. Surface-enhanced Raman spectroscopy (SERS) enhances the spectral
signature of myofibers mounted on nanostructured gold-slides when
compared to myofibers mounted on glass slides. ....................................... 152
Figure 5.3. Average control, claudicating, and CLI patient SERS. .............................. 153
Figure 5.4. Eigenvalues of partial least squares factors. The first six PLS factors
account for most of the variance (>75%). .................................................. 154

xvii
Figure 5.5. Partial least squares regression model using six PLS factors was able to
predict patient ABIs with a correlation coefficient of 0.99 and 0.85 in
training and full cross validation, respectively. .......................................... 155
Figure 5.6. Partial least squares regression β coefficients. ........................................... 156
Figure 5.7. PLS factor scores plot. A) PLS 1 and 2 grouped and separated control
patients from claudicating and CLI patients. B) PLS 1 and 3 separated
claudicating and CLI patients. These three PLS factors in a discriminant
analysis with cross validation, classified patients with 100% accuracy. .... 157

1

CHAPTER 1 : INTRODUCTION
1.1 BACKGROUND OF PERIPHERAL ARTERIAL DISEASE (PAD)
Peripheral arterial disease (PAD), also known as peripheral vascular disease
(PVD) or peripheral artery occlusive disease (PAOD), is a vascular disease characterized
by atherosclerosis and stenosis (abnormal narrowing) of the non-coronary arteries (Hirsch
et al., 2006). PAD is a slowly progressive disease that develops over many years and
often goes unnoticed (Norgren et al., 2007). In the early stages of PAD most people have
no symptoms, but have an atherosclerotic condition that is the underlying problem with
PAD (Feinglass et al., 1999; Allison et al., 2007). Atherosclerosis is a hardening of the
arteries which occurs when fatty deposits, cholesterol, and plaque buildup on the inner
linings of the arterial walls (Bonow et al., 2011). This atherosclerotic condition causes
vascular channels to harden, narrow, and lose elasticity resulting in reduced blood flow to
the limbs generally expressing symptoms in the lower extremities. Although PAD affects
a large range of arterial beds, most occlusions occur in the arteries of the legs, pelvis, and
abdominal aorta (Hirsch et al., 2006). Ambulatory pain caused by inadequate blood flow
and muscle damage in the lower extremities is known as claudication. The physical
manifestations of PAD are outward presentations of a myopathy secondary to the
vascular disease. Claudication is one of the first manifestations of PAD and is an early
indicator of muscle disease, in which myofibers begin to deteriorate due to altering
metabolic processes resulting in changes of muscle morphology. Other advanced clinical
manifestations of PAD are pain while at rest, non-healing foot ulcers, and gangrene.
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1.2 SIGNIFICANCE OF PAD
It is estimated that PAD affects approximately 8 – 10 million Americans (Norgren
et al., 2007). This condition becomes more common as one gets older and the number of
affected Americans is expected to increase with an increase of the elderly population. It
is estimated that approximately 12 to 20 percent of the population may have PAD by the
age of 65 (Ostchega et al., 2007). The seriousness of this disease is compounded with a
four to five times higher risk of having a heart attack or stroke.
In general, vascular diseases encompass any condition which negatively affects
the arteries, veins, and lymph vessels, with the most common underlying problem being
atherosclerosis. It is estimated that approximately 82,600,000 American adults have at
least one or more types of vascular disease (Roger et al., 2011). Other prevalent forms of
vascular disease are cerebrovascular disease (CVD) and coronary heart disease (CHD).
Among the vascular diseases, PAD is the third most prevalent. Patients presenting with
PAD symptoms are also likely to have widespread accumulation of fatty deposits in the
arteries and have coexisting forms of vascular disease (Figure 1.1) (Hirsch et al., 2006;
Bhatt et al., 2006; Suominen, 2008). Due to the systematic buildup of atherosclerosis
over many years, patients with PAD commonly have arterial occlusions in other vascular
locations such as the brain and heart. Moreover, data from the Reduction of
Atherothrombosis for Continued Health (REACH) Registry, a large international registry
with patient data for symptomatic atherothrombosis with CHD, CVD, and PAD, reports
that patients with PAD have highter rates of polyvascular disease when compared to
patients with CAD or CHD (Bhatt et al., 2006).
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Figure 1.1. Coexistence and distribution of three most prevalent forms of vascular
disease. Coronary heart disease (CHD), cerebrovascular disease (CVD), and peripheral
arterial disease (PAD). Modified from: (Bhatt et al., 2006)

1.2.1 Economic impact
Prevalence of PAD produces a considerable public health burden in terms of
economic cost as well as decreased quality of life. PAD is becoming increasingly
recognized as a major cardiovascular public health burden due to its increased risk of
polyvascular disease and the increased probability of patients having a major
cardiovascular ischemic event (Bhatt et al., 2006). It is estimated that approximately
260,000 revascularization procedures are performed each year in the United States
(Feinglass et al., 1999). Additionally, in the 1990’s it was reported that approximately
100,000 amputations occur each year in the U.S. (Tunis et al., 1991). This number
increased to 160,000 amputations each year in the United States, in 2004 (The Sage
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Group, 2004). Among these patients that undergo limb amputation, there is a 60%
chance of surviving the next 2 years of life. Based on a 2004 U.S. census, the total
estimated annual cost of PAD, associated with vascular-related procedures and
hospitalizations, was in excess of $21 billion dollars (Mahoney et al., 2008). According
to the Sage Group, this number could be reduced by $2.9 billion if the number of
amputations were reduced by 25% (The Sage Group, 2004). Amputation is considered to
be a medical failure to treat the disease and controlling the health care costs of PAD
represents a major challenge.
1.2.2 Severity of PAD and Survival
As PAD severity increases the risk of limb loss and mortality increases as well. It
is estimated that once a patient has been diagnosed with critical limb ischemia 20% of
those will die within the first year (Figure 1.2) and another 35% will require amputation
(Norgren et al., 2007; The Sage Group, 2004). Limb loss is closely linked to a significant
reduction in quality of living and many patients will require mobility assistance for the
rest of their lives, which can be a difficult and emotional issue. Major amputations are
not only undesirable disfiguring operations, but also carry high perioperative mortality
and morbidity rates. Perioperative mortality rates during amputation range from 4%-30%
and have morbidity rates from 20%-37% (The Sage Group, 2004). Furthermore, it is
estimated that only 40% of patients that have below-the-knee operations and only 20%
that undergo above-the-knee amputations ever return to full mobility (The Sage Group,
2004).
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Figure 1.2. Mortality of patients presenting with peripheral arterial disease. IC –
intermittent claudication; CLI – critical limb ischemia. Courtesy of: (Norgren et al.,
2007)

1.3 STATEMENT OF THE PROBLEM
Peripheral arterial disease (PAD) is an aging-related disease affecting more than
10 million patients in the United States (Norgren et al., 2007; Hiatt et al., 1995). PAD
produces a considerable public health burden (Mahoney et al., 2008; Mahoney et al.,
2010) and the ability to profile the biochemical alterations and characterize the extent of
muscle damage due to the disease would provide physicians with objective measures to
diagnose, monitor muscle degeneration, and develop patient-specific treatments. The
fundamental problem in PAD patients is the presence of atherosclerotic blockages in the
arteries supplying blood to their legs. The pathophysiology of PAD involves changes
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occurring on multiple levels including, reduced blood flow, altered metabolic processes,
and muscle degeneration (Stewart et al., 2002). Repeated cycles of ischemia followed by
reperfusion, occurring with basic daily activities, initiates a myopathy causing muscle
degeneration and can produce foot ulcers, gangrene, and eventual limb loss (Hedberg et
al., 1988a; Pipinos et al., 2008; Pipinos et al., 2008b). There is a fundamental gap in
monitoring muscle degeneration progression and regression before and after vascular
reperfusion surgeries. Limb hemodynamics, such as Ankle Brachial Index (ABI) is the
current gold standard in diagnosing and monitoring treatment interventions of PAD.
Other advanced methods such as, ultrasonography, venous plethysmography,
angiography (x-ray) or (MRA), have been employed to characterize PAD based on
monitoring blood flow. However, all these methods have limitations in monitoring
progression and regression of PAD because there is a need to measure more than just
blood flow; there is a need to measure muscle degeneration as well. The contribution of
this dissertation is to develop and evaluate direct measurements of biochemical
alterations and muscle degeneration in PAD muscle. This contribution is significant
because it represents a next step in PAD muscle degeneration research, which is expected
to advance the field in directing therapeutic intervention and monitoring clinical
treatment interventions of PAD.
Optimal diagnosis and treatment monitoring of PAD requires objective, specific,
and measureable quantification of the extent and type of damage present in a PAD
patient. This study proposes the use of morphometric determinants, biochemical
(mechanisms-based biomarker expressions), and spectral (Raman spectroscopic
parameters) of myofibers, in needle biopsies of the gastrocnemius, as tools
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complimentary to traditional diagnosis/monitoring procedures, providing objective
criteria for therapeutic interventions.

1.4 OBJECTIVES
In this study, we will evaluate the hypothesis that morphometric determinants,
biochemical (mechanisms-based biomarker expressions), and spectral (Raman scattering)
parameters of myofibers, in needle biopsies of the gastrocnemius, discriminate PAD
patients from controls and quantify disease severity, providing objective criteria for
therapeutic interventions.
1.4.1 Specific objectives of this research are to:
i.

Develop quantifiable morphometric parameters of PAD and control
myofibers that objectively discriminate stages of PAD and model the
biological phenomenon, with advanced mathematical modeling.

ii.

Quantify oxidatively altered proteins (hydrazide-reactive carbonyls) with
mechanisms-based molecular biomarkers and mathematically model disease
progression based on a combination of morphometrics and oxidative damage.

iii.

Identify Raman scattering spectral signatures of the muscle biochemistry
unique to PAD patients and correlate patient blood flow (ABI) with
identified Raman spectral signatures.

The development, evaluation, and validation of advanced mathematical models of
the myopathy of PAD will lead to:
a. Development of patient-specific treatment plans by providing information that
reflects underlying pathophysiology (levels of injury in the muscle), which allows
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the development of individualized therapy, replacing the less effective “one size
fits all” approach;
b. Improved monitoring of established (in daily clinical practices) and novel (in
clinical trials) treatment strategies.

1.5 DISSERTATION ORGANIZATION
Chapter 2 presents a literature review of key concepts related to this dissertation
project, including a background of PAD, risk factors, and diagnostic methods. The
chapter will include, in addition, a review of muscle physiology, bioenergetics, and
vibrational spectroscopy.
There are three main phases to this project. Objective I, covered in Chapter 3, deals
the development of a grading index to grade muscle deterioration of PAD patients based
on morphometric parameters of muscle fibers. Objective II, covered in Chapter 4,
provides a mathematical model to characterize PAD disease progression based on a
combination of morphometrics and oxidative damage of the myofibers. Objective III,
covered in Chapter 5, demonstrates the ability to capture a molecular profile of PAD
muscle using vibrational spectroscopy. Following these chapters a summary and
suggestions for future research are provided.
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CHAPTER 2 : LITERATURE REVIEW
2.1 DIAGNOSIS & CLINICAL MANIFESTATIONS
2.1.1 Risk Factors
Since PAD is a manifestation of atherosclerosis, the underlying problem in vascular
diseases, classic risk factors for developing atherosclerosis are also risk factors for
developing PAD. Risk factors that increase likelihood of developing lower extremity
PAD include male sex, age per 10 years, cigarette smoking, diabetes, dyslipidemia,
hypertension, race, C-reactive protein, renal insufficiency, and hyperhomocysteinemia
(Hirsch et al., 2006; Norgren et al., 2007). Figure 2.1 presents the approximate odds
ratios for these risk factors. Several investigations have reported that most of these risk
factors appear to be independent of each other and their effects become additive (Norgren
et al., 2007).
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Figure 2.1. Range of odds ratios of risk factors for developing symptomatic peripheral
arterial disease. Modified from: (Norgren et al., 2007)
2.1.2 Smoking
Among these etiological risk factors for PAD, cigarette smoking is one of the most
important and can increase the risk of developing PAD by up to three times (Figure 2.2)
(Norgren et al., 2007; Criqui et al., 1997). In other larger investigations even higher
levels of risk, as much as 2 to 6 fold increases, for developing PAD and increasing
severity of PAD, are attributed to smoking (Kannel and McGee, 1985; Smith et al., 1990;
Bowlin et al., 1994). Approximately 80% of patients with lower extremity PAD were
found to be either current smokers or were smokers previously (Smith et al., 1990; Meijer
et al., 1998). The number of cigarette packs smoked per year has a direct correlation with
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an increased risk of limb amputation, increased disease severity, and mortality (Norgren
et al., 2007).

Diabetic x4

Smoker x3

ABPI <0.5 x2.5

Age >65 x2

Risk of
developing
PAD

Figure 2.2. Approximate magnitude of increase in risk of developing PAD based on
identified risk factors. Modified from: (Norgren et al., 2007)

2.1.3 Diabetes mellitus
Similarly, patients with diabetes mellitus have an exceptionally higher risk of
developing PAD. The duration and severity of diabetes has been found to be
proportional to the risk of developing PAD (Beks et al., 1995). Furthermore, diabetic
patients that develop PAD, also have a 7 to 10 fold increase in likely hood to undergo a
major amputation (Most and Sinnock, 1983). Progression of PAD severity is also more
aggressive in patients that have diabetes. Other studies have also shown that patients that
do not have diabetes, but have insulin resistance have a 40% to 50% increase in risk for
developing PAD (Muntner et al., 2005).
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2.1.4 Age & Gender
Prevalence of PAD increases as one gets older. It is estimated that 12-15% of the
population above the age 65 has PAD (Ostchega et al., 2007) and the number of affected
Americans is expected to increase with an increase of the elderly population (Feinglass et
al., 1999). In the National Health and Nutrition Examination Survey 1999-2004, data
was collected from 3,947 men and women above the age of 60 who had lower extremity
PAD. In that study they observed that PAD prevalence was 7% among those who were
60-69 years of age, 12.5%, and 23.2% prevalence for patients between 70 to 79 and 80 to
older, respectively (Ostchega et al., 2007). As a whole, PAD generally increases steadily
beyond the age of 50 with increases in the range of 3% to 18% and further increasing to
25% and 30% beyond the age 75 (Ostchega et al., 2007; Meijer et al., 1998).
In addition to age, gender has been shown to play a role in PAD prevalence, as
well. In the Framingham Heart Study, a large cohort of 2336 men and 2873 women
between the ages 28 and 62 were examined for PAD prevalence. The investigators
observed that PAD was twice as prevalent in men when compared to women (Kannel et
al., 1970). Figure 2.3 displays the results of a study (Criqui et al., 1985) that shows both
PAD prevalence increasing with age and that men have a higher occurrence of PAD than
women.
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Figure 2.3. PAD prevalence increases as one gets older. PAD is more common among
men. Courtesy of (Criqui et al., 1985).
2.1.5 Race
Some investigations have displayed evidence that suggests that ethnic background
plays a role in the evolution of symptomatic peripheral arterial disease as well (Kullo et
al., 2003). A study performed by The National Health and Nutrition Examination Survey
in the United States reported that PAD was more common in non-Hispanic Blacks with a
7.8% prevalence compared to a 4.4% prevalence among Whites. The Genetic
Epidemiology Network of Ateriopathy (GENOA) study reported that this difference in
PAD prevalence between races was not explained by differences in the classical risk
factors and confirmed that there is indeed an effect due to race. In a large study,
conducted by Selvin et al. (2004), 2,174 patients of ages 40 years and over, similar
results were reported indicating that blacks are disproportionately affected by PAD
(Selvin and Erlinger, 2004). In addition to African-American individuals, the National
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Health and Nutrition Examination Survey also showed that Mexican-American women
reported higher prevalence of PAD when compared to non-Hispanic white men and
women (Ostchega et al., 2007).
2.1.6 Ankle Brachial Index (ABI)
Diagnosis of PAD depends upon a physical examination that focuses on the
circulatory system of the patient. The ankle-brachial index (ABI) has become the clinical
hallmark measurement to assess the vascular haemodynamics for the initial diagnosis of
PAD. An ABI measurement is performed by measuring the systolic blood pressure of the
ankle, with a 10−12 cm sphygmomanometer cuff and normalizing it with the systolic
blood pressure of the brachial artery. Figure 2.4 displays values of the ankle-brachial
index and the corresponding diagnosis. If a patient presents with an ABI of less than 0.90
they will be diagnosed with PAD. Patients presenting with ABI’s of 0.41 – 0.90 are
considered to have moderate PAD, while patients presenting with ABI’s less than 0.40
are considered to have severe PAD. In a healthy patient the normal resting ABI will be
approximately equal to one, meaning that the systolic blood pressure in the brachial
artery of the arm is similar to that of the systolic blood pressure of the ankle. An ABI
value around one indicates that there are no significant blockages or narrowing in the
arteries of the lower extremities. ABI’s greater than 1.3 are indicative of noncompressible or calcified arteries and patients presenting with high ABI’s should undergo
further vascular circulation assessment.
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Ankle Brachial Index
>1.3
Non-compressible
1.00 − 1.29
Normal
0.91 – 0.99

Borderline PAD

0.41 – 0.90

Mild-to-moderate PAD

0.00 – 0.40

Severe PAD

Right-arm
systolic pressure

Right-ankle
systolic pressure

Left-arm
systolic pressure

Left-ankle
systolic pressure

Figure 2.4. Ankle brachial index (ABI): Modified from: (Norgren et al., 2007)
The Ankle-Brachial index is generally accepted as an inexpensive, noninvasive,
rapid method of screening, diagnosing, and managing PAD. Although many clinicians
report that the ABI procedure in not reimbursable through insurances and is therefore
often not performed as a screening or prevention measure. In the clinical setting, ABI’s
can be acquired within 15 minutes and most clinicians believe that it is a useful tool in
the diagnosis and management of PAD. Literature reports indicate that ABI is able to
detect a stenosis of 50% reduction in the artery lumen with sensitivity (true positive rate)
of 79% and specificity (true negative rate) of 96% (Lijmer et al., 1996). These numbers
suggest ABI is a sufficient tool to diagnose PAD. An additional evaluation of 35 patients
with claudication measured 7 different times demonstrated that the ABI’s can be
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consistent as well, with a standard deviation of 0.07 (Baker and Dix, 1981). Other
studies reported similar variances and overall the ABI measurement is expected to have a
reproducibility of 0.10, with most of the variation coming from the measurement method
and not due to the differences between observers (Carter, 1969; Strandness et al., 2002;
Yao, 1970).
In addition to PAD diagnosis, ABI is also a good predictor of survival rates and
future cardiovascular events. In a large study of nearly 2000 claudicating patients it was
shown that patients with an ABI <0.50 had twice the mortality rate when compared to the
patients with ABI>0.50 (Dormandy and Murray, 1991). This study demonstrated that
there is a strong correlation between ABI and mortality. Other investigations observed
that there is an inverse relationship between increasing ABI and the odds of a patient
having a major cardiovascular event. As the ABI’s decrease the risk of myocardial
infarction, stroke, or death significantly increases (Mehler et al., 2003). Figure 2.5
displays this inverse relationship between ABI and the odds of a major cardiovascular
event.
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Figure 2.5 There is an inverse relationship between ABI and the odds of having a major
cardiovascular event. The lower the ABI the higher the odds of having a myocardial
infarction, stroke, or death. Courtisy of: (Mehler et al., 2003)

In another study, McLafferty et al., (1997) investigated the use of ABI to monitor
the progression of lower extremity PAD after revascularization procedures (McLafferty
et al., 1997). In that study, the criterion used to judge PAD progression was a 0.15
change in the ABI as well as other clinical measures acquired 3 years post operation.
They reported that ABI was able to monitor PAD progression with a sensitivity of 41%, a
specificity of 84%, and an overall accuracy of 68%. Based on these numbers ABI’s may
not be sufficient to monitor progression of PAD. Although, previously mentioned studies
suggest that ABI is a good diagnostic measure of PAD, the accuracy rates reported by
McLafferty et al. suggest that ABI may not be suitable for monitoring progression of
PAD.
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Despite the usefulness of ABI to predict survival and diagnosis of PAD, other
studies highlight the limitations of the ABI. Duerschmied et al. (2010) argue that noninvasive tests such as the ABI lack reliability, especially in patients with local edema or
incompressible arteries (Duerschmied et al., 2010). In their study they suggest using
contrast ultrasound perfusion imaging of the calf muscle as a viable alternative. They
claim that contrast ultrasound could help in monitoring the limb hemodynamics even
when patients have edema or incompressible arteries. Another study suggests that other
supplementary methods of diagnosis should be considered especially when there is
clinical suspicion of PAD with an ABI close to 0.90 (Nam Su Chung et al., 2010). Stein
et al. (2006) demonstrated that the sensitivity for detecting PAD with a resting ABI is
only high when there is a high grade of stenosis (>50% narrowing of the artery) and that
some patients who have PAD can present with normal ABI’s, but after limb exercise they
present with a decrease in the ABI. In their study they reported that even patients with
rest pain and/or foot ulcerations had normal ABI’s 51% and 44% of the time. Within this
group of PAD patients, with normal ABI’s, exercise testing followed by ABI disclosed
abnormalities in the blood flow that are consistent with PAD. Therefore, the ABI can be
enhanced by combining ABI with exercise testing (Stein et al., 2006).
Kramer (2007) raised the concern that ABI’s and other limb hemodynamic
measurements only measure the burden of plaque buildup on the circulatory system and
do not measure the end-organ effects of the plaque buildup (Kramer, 2007). Although
one can speculate that there will be a correlation between the end-organ damage and the
ABI, this is a problem when patients present with normal ABI s, but have PAD.
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Knowing the plaque buildup is not enough, there is also a need to measure the damage
caused by the abnormal blood flow and the overall effect on limb function. These types
of arguments were raised when clinicians and researchers noticed that even after
revascularization procedures patients continued to have a decline in walking parameters
(Regensteiner et al., 1993; Gardner and Killewich, 2001). The continued decline of limb
functional parameters, such as slower walking velocity, poorer standing balance, slower
time to arise from a seated position, suggests that there are continued end-organ effects
on the limbs even after revascularization. This suggests the need to measure more than
just blood flow. Overall, the ABI measurement is effective in the initial diagnosis of
PAD, but has limitations in providing information about the state of muscle degeneration.
2.1.7 Claudication & Critical Limb Ischemia
Ambulatory pain caused by inadequate blood flow to the muscles in the lower
extremities is known as claudication. Claudication is medically defined as fatigue,
discomfort, or pain that is induced in the limbs during exercise (Hirsch et al., 2006).
Although patients can experience leg pain for many other reasons than PAD, the key
indicator of PAD is that the pain is associated with exercise. The exercise induced
ischemic conditions cause a mismatch of oxygen supply and increased demand within the
muscle during exercise, resulting in cramping, pain, fatigue, and discomfort. Upon
cessation of exercise and returning to a resting muscle state, the aching, fatigue, and
cramping disappears. Hence the term intermittent claudication is often used to describe
this condition. Claudication is one of the first manifestations of PAD and is an early
indicator of the onset of muscle disease. In Latin the term claudication literally means
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‘limping’. These symptoms are most commonly experienced in the lower limb
musculature such as the calf muscle, but also occur in the thigh or buttocks.
The pathophysiology of claudication is more complex than what can be explained
by the mismatch of blood flow and oxygen demand (Hirsch et al., 2006). The
pathophysiology of claudication involves more complex events such as metabolic,
neurological, and inflammatory responses (Hirsch et al., 2006). In fact, all of the
physiological changes that occur during claudication are not fully understood.
Critical limb ischemia (CLI) is an advanced stage of PAD in which, patients
experience pain due to inadequate blood perfusion while at rest (Hirsch et al., 2006).
Unlike claudicating patients, CLI patients experience rest pain because they have muscle
damage, neurological damage, and have increased blockages that produce a mismatch in
oxygen supply and demand even while at rest. This condition often produces non-healing
foot ulcers, gangrene, and often leads to amputation. The pain associated with CLI can
be intense and often disturbs sleep. Some investigators have even reported that the
quality of life, for a CLI patient, can be worse than patients with terminal cancer (Vale et
al., 2001; Dormandy and Rutherford, 2000).
2.1.8 Fontaine stages & Rutherford’s categories
The Fontaine and Rutherford classification schemas provide further methods of
stratification for the diagnosis of PAD, beyond the use of ABIs. These methods are not
typically used in everyday clinical practice and are more widely used in research studies.
The Fontaine stages of PAD were among the first clinical classifications of PAD,
developed in 1954. Fontaine et al. identified four stages of PAD, displayed in Table 2.1
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(Fontaine et al., 1954). In Fontaine Stage I, patients do not present with claudication or
critical limb ischemia and are considered asymptomatic. Fontaine Stage II is divided into
two subcategories, namely stage IIa and stage IIb. In stage IIa patients begin to
experience intermittent claudication after walking distances greater than 200 m. In stage
IIb patients begin to experience intermittent claudication before reaching a walking
distance of 200 m. Stage III characterizes patients who begin to have rest pain, while
stage IV patients present with ischemic ulcers or gangrene. The Rutherford classification
is a slightly more recent modification of the Fontaine stages, with a higher level of detail
for the variation observed in the progression of PAD. The Rutherford classification
schema includes six clinical categories to classify PAD patients (Rutherford et al., 1997).
Table 2.1. Fontaine stages and Rutherford categories are often used in research studies to
quantify stages and progression of PAD. Source: (Fontaine et al., 1954; Rutherford et al.,
1997)

FONTAINE
Stage
I
IIa
IIb

Clinical
Asymptomatic
Mild
claudication
Moderatesevere
claudication

RUTHERFORD
Category
0
1
2
3

III
IV

Ischemic rest
pain
Ulceration or
gangrene

4
5
6

Clinical
Asymptomatic
Mild
claudication
Moderate
claudication
Severe
claudication
Ischemic rest
pain
Minor tissue
loss
Ulceration or
gangrene
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2.2 MUSCLE MORPHOLOGY
2.2.1 Muscle Ultrastructure
Human skeletal muscle is made up of a complex three dimensional arrangement
of numerous myofibers, myofibrils, and myofilaments. Individual myofibers are bundled
together to form fascicles, as shown in Figure 2.6. Encircling each fascicle is a very thin
connective tissue known as the perimysium. Within the fascicle, each myofiber is
encapsulated by another connective tissue known as the endomysium, which is situated
above the sarcolemma (muscle cell membrane) that surrounds the individual myofibers.

Figure 2.6. Organization of mammalian skeletal muscle structure. Image courtesy of
(Silverthorn, 2004)
A muscle fiber is a multinucleate cell that is further made up of many individual
units of myofibrils Figure 2.7. Most of the intracellular volume of the muscle fiber
consists of myofibrils. In fact, each muscle fiber can contain up to a thousand myofibrils
(Silverthorn, 2004). Within the myofiber and below the sarcolemma, each myofibril is
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surrounded by the sarcoplasmic reticulum (SR), shown in Figure 2.7. The sarcoplasmic
reticulum plays an integral part in the sequestration and release of calcium during muscle
contraction.

Figure 2.7. Ultrastructure of an individual myofiber made up of many myofibrils. Image
courtesy of (Silverthorn, 2004).
Myofibrils, which make up individual myofibers, consist of yet another complex
architecture of elements known as myofilaments, as seen on Figure 2.8. There are two
main contractile protein myofilaments, namely the F-actin thin filaments and the myosin
thick filaments. The myofibril also contains other regulatory proteins, such as
tropomyosin and troponin. A zigzag structure known as the Z-disk serves as an
attachment site for the thin filaments, whereas an M-line serves as the attachment site for
the thick filaments. Together, the Z-disk, M-line, and thick and thin filaments form a
lattice structure within which the thick and thin filaments overlap each other at their ends
and lay parallel to one another (Bloom and Fawcett, 1986). A muscle myofibril consists
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of a repeating pattern of Z-disks, and thick and thin filaments. One section of the
myofibril pattern, from Z-disk to Z-disk, consists of a sarcomere.

Figure 2.8. Micro-architecture of myofibrils and myofilaments. Image courtesy of
(Silverthorn, 2004)
A sarcomere is the smallest contractile unit of the muscle. The overlapping
portions of the thick and thin filaments within the sarcomere are connected via myosin
heads known as cross-bridges. The myosin heads are clustered on the ends of the myosin
thick filaments. The repeating sections of overlapping thick and thin filaments create
striated band patterns that can be seen in muscle tissue. The M-line and thick filaments
make up the A-band, whereas the Z-disk and thin filaments make up the I-band. The Hzone is the portion in the middle of the thick filaments where there is no overlap with thin
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filaments (Guyton and Hall, 2006). When viewed on end, each thick filament is
encircled about by six thin filaments. The myosin heads of the thick filament have a
natural affinity to the F-actin thin filament binding sites. Hence the natural state of the
muscle is rigor; however, in living muscle, relaxation is allowed to occur due to the
presence of adenosine triphosphate (ATP) and regulatory proteins such as troponin and
tropomyosin (Rayment et al., 1993).
2.2.2 Contraction-Relaxation cycle of muscle
The sliding filament theory explains that as a muscle contracts the Z-disks of the
sarcomere move closer together, but the A-band stays the same length. Additionally, as
the muscle contracts the I-band and H-zone almost completely disappear. These
observations suggest that the thick and thin filaments slide past each other, pulling the Zdisks closer together and causing contraction. The force that slides the thin filament
along the thick filament comes from the myosin heads of the thick filament.
Myosin heads play a key role in muscle contraction because they are able to bind
and hydrolyze adenosine triphosphate (ATP). Each myosin head is a motor protein that
is able to convert chemical bond energy into mechanical energy. The myosin heads are
essentially enzymes (ATPase) that can convert ATP into adenosine diphospate (ADP).
The thick filaments have many myosin heads that can swivel and bind to the thin
filaments.
The muscle contraction-relaxation cycle begins with the muscle in the rigor state.
In living muscle, the rigor state occurs for only a short moment until ATP binds to the
myosin heads resulting in conformational changes that alter the actin binding affinity of
the myosin head. The binding site of the myosin heads then close in around the ATP
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molecule hydrolyzing it to ADP and inorganic phosphate. The energy released causes the
myosin head to rotate into a 90o position and connect to the next thin filament binding
site (Silverthorn, 2004). The rotation to the 90o position cocks the myosin head back,
giving it stored potential energy to execute the power stroke. The power stroke begins by
releasing the high energy inorganic phosphate molecule causing the myosin head to
spring back to a 45o position. As the myosin head rotates back to the 45o position, it
pushes the thin filament toward the center of the sarcomere. At the end of the power
stroke, ADP is fully released, leaving the myosin head attached to the actin binding site
of the thin filament resuming the rigor state (Guyton and Hall, 2006).
Muscle contraction is regulated by two regulatory proteins, troponin and
tropomyosin. Tropomyosin is an elongated protein that wraps around the thin filament.
Tropomyosin regulates the contraction-relaxation cycle by covering the myosin binding
site of the thin filament. The position of tropomyosin is controlled by a calcium binding
protein, troponin. In the presence of high calcium concentrations, troponin causes a shift
in tropymyosin exposing the myosin binding side allowing contraction to occur
(Silverthorn, 2004).
PAD patients often experience ambulatory pain caused by inadequate blood flow
to the muscles in the lower extremities. These ischemic conditions do not allow the
contraction-relaxation cycle to operate normally. In fact, the whole cycle slows
significantly as the internal leg environment changes from aerobic to anaerobic
conditions, shutting down the Krebs cycle resulting in a significant decrease in ATP
energy production (Silverthorn, 2004). Hence, PAD patients often experience cramping,
fatigue, and aching in the lower limb musculature (Hirsch et al., 2006; Norgren et al.,
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2007). Ambulatory pain due to the mismatch in oxygen supply and demand is known as
claudication. Claudication is one of the first and most common manifestations of PAD
and is an early indicator of the onset of muscle disease.
2.2.3 Morphology
PAD produces a progressive accumulation of ischemic injury to the limbs. This
ischemic injury is reflected in a gradual worsening in the microscopic morphology of the
gastrocnemius (calf muscle). Morphological analyses of PAD muscle degeneration have
been thus far largely qualitative by pathologists’ subjective visual inspection of muscle
tissue with a microscope. Qualitative histological descriptions are useful, however,
objective, quantitative determinations offer greater precision and reproducibility for
scientific study as well as diagnosis and prognosis.
Figure 2.9 displays the morphology of normal muscle which has polygonal
myofibers of uniform size and shape, fascicles with thin perimysium, and peripherally
located nuclei. Moderately myopathic muscle cells, from a patient with claudication,
have an increased variation in shape and size and begin to develop fiber vacuolization
and target lesion with centrally located nuclei, as shown in Figure 2.10.
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Figure 2.9. Healthy, normal muscle morphology.

Figure 2.10. Moderate myopathic myofibers from a PAD patient.
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In severely myopathic myofibers (Figure 2.11), from a patient with critical limb
ischemia, group atrophy begins to appear with myofiber vacuolization, target lesions,
centrally located nuclei, and thicker interstitial tissue that is more fibrotic. At this stage,
some myofibers will have lost 90% of their contractile element. As injury advances, the
patients’ clinical condition deteriorates from being asymptomatic to having claudication
and then developing critical limb ischemia. Thus, morphology of myofibers changes
during the progression of PAD.

Figure 2.11. Severely myopathic myofibers from a PAD patient.
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2.3 OXIDATIVE DAMAGE
The pathophysiology of PAD and its end-organ effects are more complex than
what can be explained by the mismatch of blood flow and oxygen demand (Hirsch et al.,
2006). In the past, it was presumed that the manifestations of PAD were solely due to the
atherosclerotic blockages and reduced blood flow to the limbs. However, literature
reports indicate that there is a myopathy secondary to the vascular disease (Pipinos et al.,
2008b; Pipinos et al., 2008a). During walking, patients presenting with atherosclerotic
blockages in the arteries supplying their legs, experience aching, fatigue, and or cramping
as the increased metabolic needs of the limb are not being met. During rest, the
metabolic demands of the limb return to baseline and the leg is re-perfused. An
increasing number of studies suggest that these repeated cycles of ischemia followed by
reperfusion trigger inflammatory responses, compromise cellular bioenergetics, and
generate reactive oxygen species (Pipinos et al., 2008a). Additional pathophysiological
events occur at the neurological level as well (Hirsch et al., 2006).
2.3.1 Mitochondria and the Electron Transport Chain (ETC)
Mitochondria are tubular organelles, found in the cytoplasm, that play a primary
role in energy production, formation and disposal of reactive oxygen species, and as
apoptosis regulators. Mitochondria are commonly referred to as the power house of the
cell. The mitochondrial matrix, within the mitochondria, is composed of several
compartments that carry out specific energy production operations within the oxidative
phosphorylation process. Oxidative phosphorylation is a metabolic pathway that
converts adenosine diphosphate (ADP) into adenosine triphosphate (ATP) via the energy
released by the degradation of carbohydrates, pyruvate, fatty acids, and amino acids
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(Nelson and Cox, 2004). ATP is one of the primary sources of energy that directly
influences muscle performance in the human body and is often referred to as the currency
of intracellular energy transfer (Knowles, 1980).
During the oxidative phosphorylation, electrons are transferred along a series of
protein complexes known as the electron transport chain (ETC), displayed in Figure
2.12. Energy is generated through a series of reduction and oxidation reactions. Energy
generated due to electrons flowing through the electron transport chain is used to
transport protons across the mitochondrial membrane creating a proton gradient. The
electron transfer releases and the proton motive force generate approximately 200 kJ per
mole that can be used in the formation of ATP (Nelson and Cox, 2004). In the final
stage, protons are allowed to flow back across the mitochondrial membrane and a
rotational catalysis enzyme complex captures the energy produced by the proton flow,
which allows the synthesis of ATP, shown in Figure 2.12.
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Figure 2.12. Within the mitochondria ATP synthesis is driven by the energy produced
via the electron flow along the electron transport chain and the generated proton gradient.
Image courtesy of (Nelson and Cox, 2004).

During cellular respiration, in which energy production is driven by oxidation,
harmful intermediates are often produced. For instance, reactive oxygen species can be
created at complex I and complex III, during the oxidative phosphorylation process
(Nelson and Cox, 2004). One of these reactive oxygen species is a superoxide free
radical, which when converted to a hydroxyl radical it can damage other proteins,
enzymes, membrane lipids, and nucleic acids. To dispose of these harmful free radicals,
cells contain numerous antioxidant systems to counteract, detoxify, and limit damage to
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the cell. Superoxide free radicals are inactivated by a set of protective enzymes including
superoxide dismutase and glutathione peroxidase. Superoxide dismutase converts
superoxide free radicals to hydrogen peroxide and glutathione peroxidase renders the
hydrogen peroxide harmless, as shown in Figure 2.13.

Figure 2.13. Reactive oxygen species can be produced at complexes I and III in the
electron transfer chain. Superoxide dismutase is an antioxidant enzyme that helps render
free radicals harmless. Image courtesy of (Nelson and Cox, 2004)

Besides their primary role in energy production, mitochondria also participate in
regulating apoptosis. Apoptosis is a process of controlled cellular damage and death,
which takes place for the good of the organism to renew its cells. When cells receive an
external signal that triggers apoptosis, one consequence is an increase in the permeability
of the mitochondrial membrane, causing the release of cytochrome c (Nelson and Cox,
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2004). Note that cytochrome c has a dual functionality. Before the cell receives
signaling to begin apoptosis, cytochrome c is normally used in the transfer of electrons
between complexes III and IV within the electron transport chain. After receiving the
apoptotic signal cytochrome c is released to the cytoplasm where it binds to apoptotic
protease activating factors and activates proteolytic enzymes that degrade proteins.
In summary, mitochondria play a multilevel role that consists of energy
production, disposal of oxygen radical species, and regulation of apoptosis. Therefore,
dysfunction of the mitochondria would launch a cascade of problems that include a
decrease in energy production, increase in reactive oxygen species, defects in the
antioxidant abilities (superoxide dismutase enzymes). These events lead to damaged
mitochondrial DNA, and damage to apoptotic regulators. Mitochondrial studies in PAD
patients have revealed that PAD patients may have damaged mitochondria in addition to
reduced blood flow from arterial blockages (Pipinos et al., 2008; Pipinos et al., 2008b;
Pipinos et al., 2008a). These studies suggest that there is a mitochondriopathy that may
be a factor in PAD pathogenesis.
2.3.2 Mitochondriopathy
In the past, it was presumed that the only determinant of functional impairment in
PAD patients was solely due to atherosclerotic blockages and reduced blood flow to the
limbs. However, the pathophysiology of PAD and its end-organ effects is more complex
than what can be explained by the mismatch of blood flow and oxygen demand (Hirsch et
al., 2006). The idea that PAD patients may have a myopathy related to impaired
mitochondria was first introduced by Dahllof et al. in the early 1970’s. This group
performed an investigation in which they demonstrated that carbohydrate
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supplementation significantly increased muscle glycogen content and improved walking
performance (Dahllof et al., 1975). The investigation was further carried out by Hou et
al. who observed, by isolating mitochondria from PAD patients’ calf muscle, that the rate
of carbohydrate oxidation in the mitochondria were positively correlated with walking
performance and that carbohydrate metabolism was linked to impaired oxygen kinetics at
the onset of exercise (Hou et al., 2002). These data suggest that mitochondria in PAD
patients may be defective in carbohydrate oxidation and that carbohydrate
supplementation may be beneficial to improve walking parameters.
2.3.3 In vivo & In vitro evaluation of PAD mitochondria dysfunction
Additional evidence of mitochondrial dysfunction was demonstrated by Pipinos et
al. as they evaluated mitochondrial bioenergetics in vivo using phosphorus-31 nuclear
magnetic resonance spectroscopy (MRS). The MRS technology allowed them to
evaluate concentrations of ATP, phosphocreatine, and intracellular pH in real time. They
concluded, based on the MRS data, that indeed PAD mitochondria do not function
normally, and reflected an impairment of skeletal muscle bioenergetics metabolism.
(Pipinos et al., 2000) However, they also concluded that a major limitation in this
method was the inability to control or measure the external mitochondrial environment as
well as the differences in bioenergetics due to blood flow.
An investigation by Pipinos et al. (2006) further defined what components within
PAD mitochondria were failing and causing decreased bioenergetics (Pipinos et al.,
2006). In this study, they examined PAD mitochondrial oxidative phosphorylation in
vitro in a controlled environment with ample oxygen availability. The results of this
study confirmed that PAD skeletal myofibers had significantly decreased oxygen
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consumption and pointed out that the defect was coming from the electron transport
chain. They evaluated the individual complexes I through IV using in vitro respirometry
and spectrophotometric techniques to evaluate the complexes enzymatic activity in order
to isolate the defects. They found that complexes I, III, and IV, of the electron transport
chain had significantly lower mitochondrial respiration with 17%, 30%, and 17%
decreases, respectively. Similarly they found that complexes I, III, and IV also had lower
percentages of enzymatic activities at 22%, 15%, and 32% decreases, respectively
(Pipinos et al., 2006). These finding confirmed the presence of dysfunctional
mitochondria that have defects within the electron transport chain. The
mitochondriopathy is manifested by the decreased bioenergetics.
2.3.4 Oxidatively altered proteins
Dysfunctional mitochondria, especially with defects in complexes I and III, are
likely to generate enhanced amounts of free radicals. Small amounts of superoxide free
radicals occur naturally during the oxidative phosphorylation process, but when there are
defects in the complexes of the ETC, an increased amount of free radicals can be
expected. In this light and based on the results demonstrated by Pipinos et al., that show
defects in complexes I and III from PAD patients, it can be expected that PAD muscle
may generate significant amounts of reactive oxygen species (Pipinos et al., 2006). If
there are in fact elevated levels of reactive oxygen species, it would be reflected in an
increased protein carbonylation and lipid peroxidation products. As such, Pipinos et al.
also evaluated PAD muscle for protein and lipid oxidative damage. They demonstrated
that PAD skeletal muscle had significantly elevated levels of both protein carbonyls and
lipid hydroperoxide (Pipinos et al., 2006).
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Physiological studies of patients with PAD can contain a lot of variation, due to
the presence of comorbidities, level of severity, and mode of presentation. Therefore,
Pipinos et al. confirmed their previous findings in a controlled study with rodents
subjected to inflow arterial ligation to resemble moderate to severe PAD (Pipinos et al.,
2008). They hypothesized that in the absence of comorbidities (i.e. diabetes, smoking,
etc. found in human studies) they would still see myopathy with mitochondrial
dysfunction and oxidative damage. The results obtained with the chronically ischemic
mouse model were consistent with the results found in the human PAD muscle studies.
Again they found that the skeletal muscle from the ischemic mouse sustained substantial
oxidative injuries with increased protein carbonylation and lipid peroxidation (Pipinos et
al., 2008). Increased 4-hydroxy-2-nonenal (HNE), which is produced during lipid
peroxidation, appears in higher quantities during oxidative stress. To test for elevated
levels of lipid peroxidation, they labeled mouse muscle cross-sections mounted on slides
with fluorescent biomarkers specific for HNE-protein adducts. Figure 2.14 illustrates
that ischemic mouse muscle had higher levels of HNE adducts, indicated by increased
labeling of the HNE fluorescent biomarker, yielding a brighter image compared to the
control mouse muscle.
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Figure 2.14. A) Control and B) ischemic mouse muscle were labeled with fluorescent
biomarkers specific for HNE-protein adducts. Evidence of lipid peroxidation is
manifested by increased levels of 4-hydroxy-2-nonenal (HNE) labeling, yielding a
brighter image in the ischemic mouse muscle. Image source: (Pipinos et al., 2008)

Additionally, the authors evaluated the abundance of mitochondria within the
mouse muscle and also labeled for expressions of ATP synthase and manganese
superoxide dismutase (Pipinos et al., 2008). They found that the ischemic muscle
exhibited increased ATP synthase, and had higher expressions of manganese superoxide
dismutase when compared to control mouse muscle. Figure 2.15 B & D illustrates
higher labeling intensity for ATP synthase indicating higher mitochondrial content in the
ischemic mouse muscle. Pipinos et al. (2008) reported that although there was an
increase in mitochondrial content in the ischemic mouse muscle, the respiration or
oxidative phosphorylation was still lower compared to the controls. These results were
consistent with other work indicating that PAD is associated with a significant increase in
mitochondrial content in skeletal muscle (Brass and Hiatt, 2000). Figure 2.15 F presents
higher labeling intensity for manganese superoxide dismutase, which is part of the
antioxidant defense for cells and is an enzyme that renders superoxide free radicals
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harmless. The higher intensity labeling of this enzyme indicates that there are higher
levels of oxidative stress in the ischemic mouse muscle compared to the controls.

Figure 2.15. A & C present control and B & D present ischemic mouse muscle labeled
with antibodies against ATP synthase, where A & B are at a higher magnification. The
higher intensity labeling in B & D indicate higher mitochondrial content in ischemic
mouse muscle. E presents control and F presents ischemic mouse muscle labeled with
monoclonal antibodies specific for manganese superoxide dismutase. The higher
intensity in E indicates higher levels of the dismutase in ischemic mouse muscle. Source:
(Pipinos et al., 2008)
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All of these findings support the idea that PAD is not exclusively a consequence
of compromised blood flow, but also includes a myopathy with mitochondrial
dysfunction that yields decreased bioenergetics and produces oxidative damage to the
muscle cells.

2.4 VIBRATIONAL SPECTROSCOPY
2.4.1 Electromagnetic radiation
Electromagnetic radiation (light) is a complex form of energy that has both
electric and magnetic field components and exhibits wave like behavior as it travels
through space (Pedrotti et al., 2007). Propagation of electromagnetic radiation is
mathematically quantified by its frequency (ν), wavelength (λ), and characteristic speed
(c= 3 x 108 m/s). The relationship between wavelength (m), frequency (Hz or s-1), and
velocity (m/s) of light is given in Equation (2.1.
(2.1)
Electromagnetic radiation carries energy away from its source as it propagates
through space. The amount of energy is directly proportional to the frequency of the
electromagnetic radiation and inversely proportional to wavelength. The relationship
between energy (J) and frequency is given in Equation (2.2.

(2.2)
Where E is energy (J) and h is Planck’s proportionality constant 6.626 x 10-34 (J∙s). The
distribution of energy levels, from the range of various frequencies, makes up the
electromagnetic spectrum, shown in Figure 2.16. High energy electromagnetic
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radiations, such as gamma rays and x-rays, have short wavelengths and high frequencies,
whereas, low energy electromagnetic radiation, such as infrared and radio, have long
wavelengths and low frequencies.

Figure 2.16. Electromagnetic spectrum. Image courtesy of (Pedrotti et al., 2007)
2.4.2 Spectroscopy
Spectroscopy is a science that quantifies interactions between electromagnetic
radiation and matter in terms of absorption, transmission, or scattering radiation
signatures. Electromagnetic interactions with molecules can often provide insight into
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the molecular structure, vibrations, and rotations of complex molecules. These
interactions can be used to identify properties of biochemical compounds (Burns and
Ciurczak, 2001). Specifically, light in the ultraviolet and near-infrared regions are
especially useful in identifying organic compounds. Spectroscopic data is often
presented in the form of a spectral plot with radiation intensity recorded as a function of
wavelength or frequency.
The theory behind spectroscopy involves central concepts such as resonance
frequencies, quantum mechanics, and the different virtual energy states that molecules
can possess. In quantum mechanics, all molecules have unique energy differences
between their ground state (stable state) and their excited virtual state (unstable state).
All molecules vibrate at specific frequencies. When the frequency of the electromagnetic
radiation matches the frequency of the molecule, resonance takes place and an absorption
signature can be detected. Light interaction with biochemicals at the molecular level
result in changes of the energy state due to light energy being absorbed. The absorbed
energy causes electrons to transition from one orbital to another. Within the infrared
region of the electromagnetic spectrum, most organic compounds will have prominent
absorption bands that correspond to vibrational energies of the compound. The region in
which these prominent bands occur is known as the fingerprint region, which is
especially useful in identifying molecules and functional groups.
2.4.3 Light Scattering
Light scattering occurs when an incident beam of light encounters a scattering
center which results in a deflection or changing of direction of the incident photons.
There are three common forms of light scattering namely, Rayleigh, Mie, and Raman
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scattering. Rayleigh and Mie scattering are elastic forms of light scattering, meaning that
the scattered light is deflected at the same frequency as the incident beam of light.
Whereas, Raman scattering is an inelastic form of light scattering, in which the scattered
light is re-emitted at a different frequency than the incident beam of light. The majority
of light scattering is due to Rayleigh and Mie scattering.
Scattering is more effective when scattering centers are small particles in
comparison to the wavelength of the electromagnetic radiation. Rayleigh scattering is
predominantly due to particles whose dimensions are smaller than the radiation
wavelength (Wolfson, 1999). An example of Rayleigh scattering is the scattering that
occurs when sunlight interacts with oxygen and nitrogen molecules in the atmosphere
(Wolfson, 1999). It has been found that scattering is more effective at shorter
wavelengths and higher frequencies (Pedrotti, 2007). This is apparent in the sky
appearing as blue; higher frequency blue light is scattered more so than lower frequency
red light. In fact, the scattering power of violet light (λ = 400 nm) is approximately 10
times as great as that of red light (λ = 700 nm) (Pedrotti, 2007).
Light scattering that occurs due to larger particles, whose size is larger relative to
the wavelength of light, is known as Mie scattering. Mie scattering occurs in mediums
such as powdered materials like sugar where light scattering is due to the surface with
larger particles. In a medium in which many oscillators are closer together, a cooperative
effect tends to cancel the scattering in all directions except along the reflection and
refraction directions (Pedrotti, 2007). However, in material that has particles that are not
perfectly ordered in a constant atomic arrangement light is scattered in other directions as
well. Although materials that have predominately Mie scattering centers have less
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scattering power, the density of oscillators leads to a considerable scattering signal
(Pedrotti, 2007).
2.4.4 Raman Spectroscopy
Most photons are elastically scattered through Rayleigh and Mie scattering.
However, a small fraction of photons, approximately 1 in 107 photons will scatter in an
inelastic manner, meaning they will undergo a change in energy compared to the incident
photons. The inelastic scattering of photons is known as the Raman Effect. Prior to the
early 1900’s inelastic scattered photons were thought to be just noise because they
produced a very weak signal. However, in 1928 C.V. Raman found that despite the weak
signal of these photons, they were molecule specific and could be used to identify
unknown compounds.
Raman scattering occurs when energy from an incident wave of light is removed
by a scattering medium via an inelastic collision (Pedrotti, 2007). As light interacts with
elemental oscillators or scattering units, the vibrations of the scattering unit are forced
into higher oscillations due to the alternating electric field of the incident wave of light.
The excited molecules reradiate or scatter the energy with frequencies higher or less than
the incident photons (Pedrotti, 2007). The change in energy level due to the Raman
Effect is called a Raman shift. If the Raman shift results in a decrease in energy it is
called Stokes Raman scattering. In other words, in Stokes Raman scattering the scattered
photon will have less energy or a longer wavelength of light compared to the excitation
incident photon. The loss of energy comes from the inelastic collision between the
photon and the molecule. Whereas, if the Raman shift yields a net increase in energy it is
called anti-Stokes Raman scattering. In anti-Stokes Raman scattering the scattered
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photon will have a shorter wavelength or higher energy level than the incident photon.
Figure 2.17 displays an energy diagram that illustrates the changes in energy levels in IR,
Rayleigh (elastic scattering), and Stokes and Anti-Stokes Raman scattering. In Raman
scattering the energy gained or lost corresponds to the vibrational energy spacing in the
molecules.
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Figure 2.17. Energy diagram depicting elastic Rayleigh scattering and Stokes and AntiStokes Raman scattering. (Sasic and Ozaki, 2010)
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Fluorescence is also a process that involves molecular excitation followed by
emission of a photon (Sasic and Ozaki, 2010). Although, fluorescence operates under
similar principles as Raman it is fundamentally different. In fluorescence, molecules are
excited to a discrete energy level, whereas, in Raman molecules can become excited to
much higher virtual energy states that are explained by involving quantum physics (Sasic
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and Ozaki, 2010). In fluorescence, molecular excitation occurs via absorption, whereas,
in the Raman Effect an inelastic collision causes the photon to gain or lose a vibrational
quantum of energy (Sasic and Ozaki, 2010). Moreover, Raman spectra produce sharp
spectral peaks that are molecule specific, whereas, fluorescence emissions are usually
broad with few spectral features. Despite their differences, both fluorescence signals and
Raman signals are present in Raman spectra. The Raman peaks usually ride on top of the
background autofluorescence signal. In Raman spectra the fluorescence signal is
generally not useful and is subtracted out via baseline correction procedures.
2.4.5 Raman active molecules vs. IR active molecules
Raman and Infrared spectroscopy both rely on vibrational energies of molecules
for detection, but each method has different selection rules (Sasic and Ozaki, 2010). In
other words, molecules that produce Raman spectral peaks generally will not appear in IR
spectra and vice versa molecules that generate IR spectral peaks will not appear in Raman
spectra. These selection rules are useful because they make the two spectroscopic
methods complementary to each other. The selection rules are related to the symmetry of
the molecule. Molecules with a symmetric configuration are said to be Raman active
because they will produce a peak in the Raman spectra (Sasic and Ozaki, 2010). For
instance, ethylene’s carbon-double-carbon (C=C), which has symmetry, will produce a
peak in Raman spectra around 1657 cm-1 (Movasaghi et al., 2007). Conversely, IR
selection rules favor asymmetric molecules. Molecules that have an asymmetrical
configuration are said to be IR active, because they will produce peaks in IR spectra
(Sasic and Ozaki, 2010). For example, a carbonyl (C=O), which has an asymmetrical
configuration, will produce an IR spectral peak at around 1700 cm-1 (Sasic and Ozaki,
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2010). Figure 2.18 presents both Raman scattering and Fourier transform infrared
(FTIR) spectra of oleic acid methyl ester. The selection rules are evident in Figure 2.18,
in which the C=C bond produces a peak in the Raman spectra and does not in the FTIR
spectra. The opposite is true for the carbonyl (C=O), producing a peak in FTIR and not
in Raman. The nature of these selection rules can become very useful, to identify
unknown compounds, using the two methods in a complementary fashion (McCreery,
2000).

Figure 2.18. Raman scattering (lower) and FTIR (upper) spectra of oleic acid methyl
ester, depict the selection rules of each spectroscopic method and their complementary
nature. Source: (McCreery, 2000)
2.4.6 Biomedical applications of spectroscopy
Raman spectroscopy has been a well-accepted analytic method in detecting
biological and chemical materials. Studies have demonstrated that Raman spectroscopy
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is capable of identifying and constructing chemical maps of subcellular structures such
as, the nucleus, cytoplasm, and mitochondria (Miljković et al., 2010; Bonnier et al.,
2010). In fact, the whole process of eukaryotic cell mitosis has been traced using time
and space resolved Raman spectra of organelles from dividing yeast cells (Huang et al.,
2003). Raman spectroscopy of biological tissues can provide information-rich,
biochemical profiles (Diem et al., 1999).
Raman spectroscopy has been used as a method for the detection of high-risk
plaques in patients with cardiovascular disease. The term, high-risk plaque, also referred
to as vulnerable plaque, describes plaque that is lipid-rich with a thin fibrous cap
(MacNeill et al., 2003). This type of plaque buildup generally has modest stenosis and
therefore is not easily identified as threatening, but often results in acute coronary
syndromes and sudden cardiac death (Muller et al., 1989). Baraga et al. developed a
Raman probe that could be used in situ to collect optical histochemistry of the arteries
(Baraga et al., 1992). The standard for characterizing atherosclerotic plaque buildup
relies primarily on morphology and extent of stenosis from the plaque. This study
provided unprecedented in vivo and in situ biochemical information of the plaque within
the arteries. The Raman probe was able to provide real time in vivo and in situ
information about the plaque composition, including cholesterol, elastin, collagen, lipids,
carotenoids, and calcium apatite deposits (Baraga et al., 1992). The authors also
remarked that this technique could collect spectral information up to 1.5 mm below the
surface allowing further histological information about the plaque.
In another study, Buschman et al. also demonstrated that Raman spectroscopy
could be used to aid in the diagnosis of coronary atherosclerosis. Raman spectra were
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collected from coronary arteries (n=200) using a Raman microscope (Buschman et al.,
2001). They developed a logistic regression model to classify coronary artery samples as
nonatherosclerotic, calcified plaque, or noncalcified atheromatous plaque. They reported
that their model was able to correctly classify, in a validation data set (n=87), the status of
the artery plaque with 94% accuracy (Buschman et al., 2001). Figure 2.19 displays
Raman spectra from their study of a normal artery, artery with lipid rich plaque, and an
artery with calcified plaque.
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Figure 2.19. Raman spectra of A) normal artery, B) artery with lipid rich plaque, and C)
artery with calcified plaque. The bottom line in each spectra is the residual between the
Raman spectra and a fitted model. Source: (Buschman et al., 2001)

In an investigation of Raman spectroscopy using live yeast cell mitochondrion, an
important discovery was made that associated a Raman spectral peak (1602 cm-1) with
mitochondrial activity. The authors named this peak the Raman spectral signature of life
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because it reflected the metabolic activity of the mitochondria (Huang, 2004). They
originally noticed this peak in the cytoplasm of a living Schizosaccharomyces pombe cell
and noticed that it appeared concomitant with the bands of phospholipids. To investigate
the origin of the 1602 cm-1 peak and to confirm that this peak was related to
mitochondrial activity, the authors added aqueous potassium cyanide (KCN) to yeast
cells and recorded Raman spectra at given time intervals. KCN is an inorganic
compound that inhibits cellular respiration. Figure 2.20 displays the effects that KCN
(respiration inhibition) had on the cell’s Raman spectra. Prior to the addition of KCN,
the Raman spectra displayed a 1602 cm-1 peak. As time passed the 1602 cm-1 peak
decreased considerably while the protein band at 1003 cm-1 did not change. Additionally,
other phospholipid bands 1446 and 1300 cm-1 began to decrease as well as time passed.
They concluded that the CN- inhibited cellular respiration and caused the 1602 cm-1 peak
to decrease. The decreased metabolic activities subsequently caused the double
membrane structure of the mitochondria to degrade which was reflected as a decrease in
the other phospholipid bands over time as well. Therefore they concluded that these
Raman spectral changes correspond to the dying process of living yeast cells. However,
the authors concluded that the exact molecular species responsible for the 1602 cm-1 peak
are unknown. Using green fluorescent proteins targeted specifically to mitochondria they
confirmed that the Raman spectra were taken from mitochondrion inside the cell.
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Figure 2.20. Raman spectral signature associated with mitochondrial activity. Source:
(Huang, 2004)
Other investigative studies have demonstrated the use of Raman spectroscopy for
characterization of other diseases and have demonstrated the scientific merit of this
technique. These other applications include characterization of biochemical changes in
disease progression for bronchial tissue (Koljenovic et al., 2004), brain tissue (Kirsch et
al., 2010), stomach ulcers (Bergholt et al., 2010), articular cartilage degeneration
(Bonifacia et al., 2010), and breast tissue (Nijssen et al., 2002).

2.5 SUMMARY
The fundamental problem in PAD patients is the presence of atherosclerotic
blockages in the arteries supplying blood to their legs. PAD affects a large range of
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arterial beds and is often concomitant with other polyvascular diseases (Hirsch et al.,
2006; Bhatt et al., 2006). PAD becomes more likely as one gets older and generally
expresses symptoms such as, cramping, pain, or tiredness in the lower extremities
(Norgren et al., 2007).
The pathophysiology of PAD is complex and involves changes occurring on
multiple levels including, reduced blood flow, altered metabolic processes, and muscle
degeneration (Stewart et al., 2002). At the level of the skeletal muscle, ischemic injury is
manifested as a gradual and characteristic degradation of muscle histology (Pipinos et al.,
2008b; Hedberg et al., 1988b; Makitie and Teravainen, 1977; Marbini et al., 1986). Thus
far, attempts to characterize PAD muscle degradation have been limited to qualitative
histopahtological assessments and limited measures of myofiber cross-sectional area
(Hedberg et al., 1988b; Makitie and Teravainen, 1977; Farinon et al., 1984). Further,
repeated cycles of ischemia followed by reperfusion, trigger inflammatory pathways and
induce the generation of reactive oxygen species (ROS) in the PAD muscle, damaging
primary organelles such as mitochondria (Pipinos et al., 2008; McDermott et al., 2004;
Pipinos et al., 2008b). Dysfunctional mitochondria then further lower the already
decreased energy levels (associated with compromised blood supply) and become sources
of increasing levels of ROS and possibly inducers of apoptosis (McDermott et al., 2004).
In this dissertation PAD muscle degeneration is characterized precisely with
mathematical equations that incorporate multiple, objectively defined parameters
including myofiber density, roundness, minor and major axes, and solidity. Based on
these myofiber morphometrics a discriminant model is presented, which can be used to
objectively grade muscle damage within clinical classifications. In addition to the
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morphometric grading scale, this dissertation combines morphometric parameters with
oxidative damage parameters to further enhance PAD muscle characterization. Finally,
this dissertation evaluates the use of Raman spectroscopy, as a label-free optical tool, to
characterize altered muscle biochemistry in patients with PAD.
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3.1 ABSTRACT
Background―Peripheral arterial disease (PAD), which affects approximately 10 million
Americans, is characterized by atherosclerosis of the non-coronary arteries. PAD
produces a progressive accumulation of ischemic injury to the legs, manifested as a
gradual degradation of gastrocnemius histology. In this study, we evaluated the
hypothesis that quantitative morphological parameters of gastrocnemius myofibers
change in a consistent manner during the progression of PAD, provide an objective
grading of muscle degeneration in the ischemic limb, and correlate to clinical stage of
PAD.
Methods and Results―Biopsies were collected with a Bergstom needle from PAD
patients with claudication (n=18) and critical limb ischemia (CLI; n=19) and control
patients (n=19). Myofiber sarcolemmas and myosin heavy chains were labeled for
fluorescence detection and quantitative analysis of morphometric variables including
area, roundness, perimeter, equivalent diameter, major and minor axes, solidity, and fiber
density. The muscle specimens were separated into training and validation data sets for
development of a discriminant model for categorizing muscle samples on the basis of
disease severity. The parameters for this model included standard deviation of
roundness, standard deviation of solidity of myofibers, and fiber density. For the
validation data set, the discriminant model accurately identified control (80.0%
accuracy), claudicating (77.7% accuracy), and CLI (88.8% accuracy) patients, with an
overall classification accuracy of 82.1%.
Conclusions―Myofiber morphometry provided a discriminant model that establishes a
correlation between PAD progression and advancing muscle degeneration. This model
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effectively separated PAD and control patients and provided a grading of muscle
degeneration within clinical stages of PAD.

Keywords: Peripheral arterial disease; Myofiber morphology; Fluorescence microscopy;
Imaging; Linear discriminant analysis;
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3.2 INTRODUCTION
Peripheral arterial disease (PAD) is a vascular disease characterized by stenosis of
the non-coronary arteries caused by fatty deposits and plaque buildup (Hirsch et al.,
2006). Although PAD affects a large range of arterial beds, most occlusions occur in the
arteries of the legs, pelvis, and abdominal aorta causing reduced blood flow to the lower
extremities (Hirsch et al., 2006). PAD is a slowly progressive disease that develops over
many years. It is estimated that PAD affects approximately 8-10 million Americans
(Norgren et al., 2007; Hiatt et al., 1995). The disease becomes more common as one gets
older and the number of affected Americans is expected to increase as the population
ages (Feinglass et al., 1999; Allison et al., 2007).
Intermittent claudication, walking impairment induced by simple exercise, is an
early manifestation of PAD (Fontaine Stage 2) (Norgren et al., 2007; Fontaine et al.,
1954) and an indicator of the damage to leg muscles (Pipinos et al., 2008a; Pipinos et al.,
2008b). More advanced disease is characterized by pain while at rest (Fontaine Stage 3)
and non-healing foot ulcers and gangrene (Fontaine Stage 4). The pathophysiology of
PAD is complex and involves changes occurring on multiple levels, such as reduced
blood flow, altered metabolic processes, oxidative damage, and degeneration of nerves
and muscle (Stewart et al., 2002). Currently, PAD is diagnosed primarily on the basis of
patient complaints about pain, non-healing wounds in the legs, and reduced limb
hemodynamics, such as the Ankle/Brachial Index (ABI; the ratio of systolic pressure in
the ankle to that in the arm). Stenoses and occlusions of the arteries supplying the legs
produce low ABIs, the hemodynamic hallmark of PAD.
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PAD produces a progressive accumulation of ischemic injury to muscles, nerves,
blood vessels, skin and subcutaneous tissues of the leg (Pipinos et al., 2008a; Pipinos et
al., 2008c; Brass and Hiatt, 2000). At the level of the skeletal muscle, this ischemic
injury is manifested as a gradual and characteristic degradation of muscle histology
(Pipinos et al., 2008b; Hedberg et al., 1988; Makitie and Teravainen, 1977; Marbini et al.,
1986). We hypothesize that quantitative morphometric parameters of gastrocnemius
myofibers change in a consistent manner during the progression of PAD, provide an
objective grading of muscle degeneration in the ischemic limb, and correlate to clinical
stage of PAD. Thus, the specific objectives of this study are to 1) quantify morphological
parameters of myofibers in gastrocnemius biopsies, 2) develop and validate a
discriminant model using morphological parameters that classify muscles as control,
claudicating, and CLI and 3) to grade the disease particularly in its early stage (Fontaine
Stage 2) on the basis of morphological measurements.

3.3 METHODS & MATERIALS
3.3.1 Tissue Sample Collection
The experimental protocol was approved by the Institutional Review Board, and
all subjects gave informed consent. We recruited 18 patients with clinical diagnosis of
claudication, 19 patients with clinical diagnosis of critical limb ischemia (CLI), and 19
controls who did not have PAD (Table 3.2). Muscle samples obtained from controls,
claudicating, and CLI patients are designated as “control”, “claudication”, and “CLI”
respectively throughout the manuscript. Biopsies of the gastrocnemius were acquired
with a Bergstom needle, fixed in methacarn and embedded in paraffin. Two 4 µm cross
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sections, taken approximately 40 µm apart, were mounted on glass slides for fluorescence
labeling.
3.3.2

Fluorescence Labeling of Tissue Sections
In preparation for labeling sarcolemma and myosin types I and II, the slide

specimens were deparaffinized with xylene and rehydrated via a series of ethanol washes
and distilled water. The rehydrated slide specimens were heated at 94 oC in Tris buffer
(pH 9.0) for 30 minutes and then allowed to cool for 20 minutes. The slide specimens
were soaked in SuperSensitive Wash buffer (SS; BioGenex Laboratories, Inc., Freemont,
CA) for 30 minutes at room temperature, with stirring. A pap pen was used to apply a
lipid barrier on dried areas around the tissue specimens. While applying the lipid barrier,
care was taken to ensure that the tissue specimens were kept moist.
A programmable autostainer (BioGenex i6000; BioGenex Laboratories) was used
to label sarcolemma and myosin heavy chains. The slide specimens were washed ten
times with SS buffer (4 min per wash) then blocked with 10% goat serum for 20 minutes.
Subsequently, the slides were treated with a mixture of anti-Type I myosin (SigmaAldrich, St. Louis, MO; M8421, clone NOQ7.5.4D) and anti-Type II Myosin (SigmaAldrich; M4276, clone MY-32) antibodies, for 1 hour. The slide specimens were washed
two times with SS buffer (4 min per wash) and then treated for 1 hour with a mixture of
wheat germ agglutinin-Alexa Fluor 350 to label the sarcolemma (Life TechnologiesMolecular Probes, Grand Island, NY; W11263) and goat anti-mouse IgG-Alexa Fluor
488 (Life Technologies-Molecular Probes; A11004). Treated slides were washed three
times with SS buffer. Finally, ProLong Gold antifade medium (Life TechnologiesMolecular Probes; P36930) was applied to the labeled specimens and covered with a
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coverslip. The slides were stored at room temperature for 24 hours and then kept at 5 oC
for subsequent fluorescence imaging.
3.3.3

Fluorescence Image Acquisition
Gray scale (12-bit) images (1344 × 1044 pixels) of gastrocnemius myofibers were

acquired with a CCD camera (Orca ER C4742-95; Hamamatsu Photonics, Bridgewater,
NJ), a Leica microscope (DMRXA2; North Central Instruments, Plymouth, MN) (10×
objective; 0.5128 µm/pixel), and Image-Pro® Plus software. Excitation energy was
delivered with a 150 W HgXe lamp (Hamamatsu Photonics).
Fluorescence images were collected from a total of 5 different locations (frames)
on each of two slides per patient. At each location, images were collected in fluorescence
channels corresponding to each fluorophore; 1) excitation at 350 nm and emission at 460
nm (Alexa Fluor 350) and 2) excitation 480 nm and emission at 535 nm (Alexa Fluor
488). The images of the sarcolemma (Figure 3.21A) were collected in the 460 nm
channel and the images of myosin (Figure 3.21B) were collected in the 535 nm channel.
In total, 20 images were collected for each patient, i.e., 10 images of the myosin signal
and 10 images of the corresponding sarcolemma signal.
3.3.4

Image Processing
To extract morphometric parameters for each myofiber, the individual myofibers

were isolated by segmentation of the fluorescence image. Image segmentation was done
with a custom algorithm written in MATLAB (R2009a Mathworks Inc. Natic, MA.),
using thresholding, edge detection, erosion, dilation, and a set of heuristics. Labeled
sarcolemma (Figure 3.21A) provided an outline of each myofiber, while labeled myosin
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(Figure 3.21B) confirmed that a given outline encompassed a myofiber, as opposed to a
fat cell or any other element of the inter-myofiber space. Myofibers on the edge of the
image were omitted from the final binary segmented image, as accurate morphometric
parameters could not be extracted from only part of fibers. The final binary segmented
image preserved the geometry of individual myofibers, as displayed in Figure 3.21C.
3.3.5

Morphometric Measures
Multiple morphometric parameters of each myofiber were measured as variables

that may discriminate PAD and control muscle, and provide an objective grading of
disease. The morphometric parameters included: 1) myofiber cross-sectional area,
calculated as the number of pixels enclosed within a segmented myofiber, 2) lengths of
major and minor axes of the myofiber, 3) myofiber perimeter, measured as the number of
pixels on the boundary of the myofiber, and 4) equivalent diameter, defined as the
diameter of a circle that has the same area as the segmented myofiber region and
calculated using Equation (3.3).
√

(

)

(3.3)

Additional morphometric parameters of each myofiber included three measures of
roundness given in Equations (3.4), (3.3) and (3.6). Multiple measures of roundness were
employed to capture the irregularities and variations of shape and geometry among
myofibers.
(3.4)
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(3.5)
(
(

)
)

(3.6)

Myofiber solidity, defined as the area of the myofiber divided by the area of a
fitted convex hull, given in Equation (3.7), was measured as well. A fitted convex hull is
the smallest convex polygon that can encompass the myofiber. A polygon is convex if it
satisfies the criterion that a line segment connecting any two points inside the polygon lie
entirely within the polygon. We selected this measure to capture the concavities or lack
of concavities in the myofibers.

(3.7)
Fiber density was defined as the area occupied by the myofibers divided by the area
occupied by the myofibers plus interstitial tissue, given in Equation (3.8).

(3.8)
Finally, a quartile analysis was performed on each tissue specimen, by which the
myofibers were separated into three groups based on cross-sectional fiber area, the lower
quartile (small fibers) denoted as ‘LQ’, the middle two quartiles (medium size fibers)
denoted as ‘M50%’, and the upper quartile (larger fibers) denoted as ‘UQ’. Quartile
analysis was performed so that morphometric parameters within the lower and upper
quartiles would not be lost in the average of the global morphometric measurements. The
mean and standard deviation of the nine morphometric parameters for all myofibers and
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for myofibers in quartiles of cross-sectional area (72 variables), in addition to fiber
density (one variable) were used to represent each patient. Thus, a total of 73 variables
for each of the 56 patients were used to build a classification model that discriminates
PAD and control muscle, and provides an objective grading of disease.
3.3.6

Discriminant Model Development
Control, claudicating, and CLI patients were assigned randomly to training (9, 9,

and 10 patients, respectively) and validation (10, 9, and 9 patients, respectively) sets.
Variable contribution analysis and model development were implemented using the
training data set. A data preprocessing step was performed to check and verify
discriminant analysis assumptions. In addition, the multivariate data were standardized
to remove units and put each variable on the same scale. Variable contribution was
analyzed using a stepwise selection procedure (Klecka, 1980; Jennrich et al., 1977) in
SAS 9.2 (The SAS Institute, Cary, NC.). Stepwise selection uses both forward selection
and backward elimination procedures while evaluating the contribution of parameters to
the discriminatory power of the model (Costanza and Afifi, 1979).
Linear discriminant analysis was used to create rules that discriminate PAD
patients and controls based on the computed morphometric variables. The discriminant
analysis was divided into two stages corresponding to two models. The first model
(Model 1) was designed to discriminate patients with CLI from the group of control and
claudicating (control/claudicating) patients. The second model (Model 2) was designed to
discriminate control patients from the claudicating patients.

80
Six morphometric variables were selected for discriminant Model 1, namely,
solidity of the lower quartile (LQ Solidity), standard deviation of the major axis from the
lower quartile (LQ Stdev. Major Axis), standard deviation of roundness2 from the global
measurements (Global Stdev. Roundness2), the standard deviation of roundness3 from
the middle two quartiles (M50% Stdev. Roundness3), standard deviation of solidity from
the middle two quartiles (M50% Stdev. Solidity), and fiber density.
The training of discriminant Model 1 consisted of 10 CLI patients and 18
control/claudication patients, each from the training data set. Note that in the training of
Model 1 the controls and claudicating patients were treated as a single group. All
patients that were classified into the control/claudication group by Model 1 were then
subsequently passed on to the next stage for analysis by Model 2.
The training of discriminant Model 2 consisted of 9 controls and 9 claudicating
patients from the training data set. Three morphometric variables were selected for
Model 2, namely, the standard deviation of roundness3 (M50% Stdev. Roundness3) from
the middle two quartiles, roundness1 from the global measurements (Global
Roundness1), and the standard deviation of solidity from the upper quartile (UQ Stdev.
Solidity).

3.4 RESULTS
Muscle degeneration in PAD exhibits multiple features that include combinations
of myofiber atrophy, loss of the normal polygonal myofiber shape, nuclear clumps,
increased numbers of internal nuclei fiber vacuolization, target lesions, myofiber
regeneration, myofiber necrosis, fibrosis and replacement of muscle by adipose tissue.
Changes from mild (Figure 3.22B) to moderate (Figure 3.22C), to severe (Figure
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3.22D), degeneration represent a continuous progression in the extent and severity of
these features. Our goal is to use linear discriminant analysis of morphometric
parameters of gastrocnemius specimens to discriminate control (Figure 3.22A),
claudicating, and CLI patients. Linear discriminant analysis is a multivariate statistical
model that seeks to establish a mathematical rule to separate two or more classes from
each other (Johnson and Wichern, 2007; Anderson, 1984; Fisher, 1936). Once a
mathematical rule is derived it can be used to optimally assign new observations into a
given classification (Johnson and Wichern, 2007).
Model 1: Linear discriminant Model 1 is given in Equation (3.9).
(
(
(

)

(

)
)

)

(

)

(

)

{

The model discriminated CLI patients and control/claudication patients with 100%
accuracy in the training data set (n=28). While validating the discriminant rule, with the
validation data set (n=28), Model 1 was able to accurately classify 8 of 9 CLI patients
(88.8%) and correctly classified 19 of 19 control/claudicating patients (100%). Further,
this model provides a grading index for progression of muscle degeneration among both
claudicating and CLI patients (Figure 3.23).
An independent t-test was used to test for significant differences in group means
of the standardized variables used in Model 1 (Figure 3.24), within the training data,
where a p-value < 0.05 was considered significant. Fiber density was significantly lower
(P =0.0005) in CLI patients (n=10; ̅ =-0.81; ± S.E.=0.38) compared to

(3.9)
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controls/claudicating patients (n=18; ̅ =0.45; ± S.E.=0.10). The ratio of fiber area to the
area of ‘fibers plus interstitial tissue’, was lower in CLI compared to control/claudication
myofibers, indicating that the interstitial tissue was thicker in CLI. An example of the
fiber density of a control muscle tissue sample, is given in Figure 3.25 (panels A, B, and
C), while, Figure 3.25 (panels D, E, and F) presents an example of the fiber density of a
CLI muscle sample.
Standard deviation of Solidity among the middle two quartiles of the fibers was
significantly lower (P <0.0001) for the controls/claudicating patients (n=18; ̅ =-0.52; ±
S.E.=0.13) compared to the CLI patients (n=10; ̅ =0.93; ± S.E.=0.31). Additionally, the
Solidity of the lower quartile of fibers was significantly higher (P =0.0021) for the
controls/claudicating patients (n=18; ̅ =0.40; ± S.E.=0.19) compared to the CLI patients
(n=10; ̅ =-0.73; ± S.E.=0.28). Both of these measures of solidity indicated that
control/claudicating patients had myofibers with fewer concavities and more uniform
solidity compared to CLI patients, as shown in Figure 3.26.
The standard deviation of global roundness2 was significantly lower (P <0.0001)
for control/claudicating patients (n=18; ̅ =-0.50; ± S.E.=0.15) compared to CLI patients
(n=10; ̅ =0.91; ± S.E.=0.26). Similarly, the standard deviation of Roundness3 from the
middle two quartiles of fibers was significantly lower (P <0.0001) for
control/claudicating patients (n=18; ̅ =-0.54; ± S.E.=0.13) compared to CLI patients
(n=10; ̅ =0.97; ± S.E.=0.27). Both of these measures of roundness indicated that CLI
patients had larger variation in roundness of their myofibers.
Model 2: Linear discriminant Model 2 is given in Equations (3.10).
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(3.10)
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The model separated controls and claudicating patients with 94.4% accuracy in the
training data set (n=18), in which 8 of 9 controls (88.0%) were correctly classified and 9
of 9 claudicating patients (100.0%) were correctly classified. In validating (n=19)
discriminant Model 2, 8 of 10 controls (80.0%) were correctly classified and 7 of 9
claudication patients (77.7%) were correctly classified, giving an overall accuracy of
78.9%.
In Model 2, the standard deviation of Roundness3 in the middle two quartiles of
fibers was significantly lower (P =0.0078) for controls (n=9; ̅ =-0.58; ± S.E.=0.30)
compared to claudicating patients (n=9; ̅ =0.58; ± S.E.=0.23) , shown in Figure 3.27.
This measure of roundness indicated that claudicating patients had more variation in
roundness when compared to control patients.
Combining the results from Models 1 & 2 yielded an overall accuracy of 96.4%,
for the training set, shown in Table 3.3 and 82.1%, for the validation set, as presented in
Table 3.4.

3.5 DISCUSSION
We have established that there are consistent and quantifiable changes in
myofiber morphology that reflect the progression of PAD muscle degeneration and offer
the possibility of an objective index for grading severity of disease within clinical
classifications, i.e., Fontaine Stage. Myofiber morphometrics were determined precisely
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with mathematical equations that incorporated multiple, objectively defined parameters
including fiber density, roundness, minor and major axes, and solidity. To the present
time, morphological studies of PAD muscle have been limited to qualitative
histopathological assessments and measurements of myofiber cross-sectional area
(Hedberg et al., 1988; Makitie and Teravainen, 1977; Farinon et al., 1984).
Currently, PAD is diagnosed and treated primarily on the basis of the patient’s
clinical presentation and the results of hemodynamic and imaging evaluation of the
arterial system of the lower limbs (Norgren et al., 2007). However, a simple histological
evaluation of skeletal muscle from PAD limbs reveals damage and degeneration and
suggests that the pathophysiology of PAD is much more complex than a decline of
hemodynamics (Pipinos et al., 2008a; Pipinos et al., 2008b). Work from our and other
laboratories evaluating skeletal muscles from PAD legs demonstrate that the PAD limb,
overtime, accumulates increasing amounts of injury that can be measured at the
molecular, biochemical, physiological and histological level (Pipinos et al., 2008a;
Pipinos et al., 2008b; Pipinos et al., 2008c; Makris et al., 2007). Likely, this injury is a
key determinant of leg function, quality of life and clinical prognosis in PAD. As we
make continuous progress in our understanding of how the leg as end-organ is being
damaged in PAD, we realize that measures much more specific and sensitive than
hemodynamic measurements or angiography must be developed in order to quantify
accurately and in a patient-specific manner the degree and type of degeneration in the
PAD limb.
In this study, we have focused on the histology of PAD muscle and have
developed a discriminant model of myofiber morphometrics, which grades myofiber
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damage in the gastrocnemius of PAD patients and provides an index of disease severity
in the end-organ. This grading index is a robust first step towards quantifying the
progression of degeneration in the PAD leg. The index is based on discriminant scores of
claudicating and CLI patients. We propose that the ranges of discriminant scores for both
claudicating and CLI patients do not represent random variation, but rather systematic
changes in disease state. The higher the discriminant score the higher the muscle
degeneration. Claudicating patients with higher discriminant scores (Figure 3.23) had
more myofiber damage similar to that of CLI patients. The presence of such advanced
muscle degeneration in patients with claudication may suggest that these patients are
prone to deteriorate to CLI. Clinicians may therefore consider more aggressive treatment
for these patients. Claudicating patients with lower discriminant scores had less myofiber
damage and may be considered for different treatment. Similarly, a grading index
(coupled to clinical findings) may help clinicians choose the CLI patients that may be
better served by revascularization, amputation or non-operative management (Nehler et
al., 2003). It is clear that prospective natural history studies will be necessary to define
the role of tissue-based indices such as the one presented in this study in the care of
patients with PAD.
Among the predictors, within Model 1 (Equation 3.7), fiber density, variation of
solidity, and roundness, had the most weight in the discriminant model. Low fiber
density reflects advanced injury characterized by fibrosis and deposition of adipose
tissue. This measurement quantifies the endomysial (in between myofibers) and
perimysial (around myofascicles) thickening that occurs with increasing muscle damage.
In normal muscle, the extracellular connective tissue is very thin and the myofibers and

86
myofascicles are in close contact. Model 2 (Equation 3.8) is essentially made up of
measures of roundness in various forms. Solidity is essentially a different measure of
roundness, which captures concavities or partial u-shapes of the fibers. Roundness
appears to represent myofiber degeneration and/or necrosis associated with loss of
sarcolemmal integrity and characterized by myofiber swelling. Adenosine triphosphate
needed to maintain the membrane ion pumps fail, producing changes in the ionic
composition of the sarcoplasm and an influx of water with subsequent swelling and
rounding of the fiber. These important changes are captured in the discriminant scores of
our morphometric analyses.
The model achieved a high level of accuracy (88%) in classifying CLI patients.
Surprisingly, the one CLI patient that was misclassified was incorrectly classified as a
control (Table 3.4). Based on the mathematics alone, the myofiber morphology of this
CLI patient (i.e. non-standardized Fiber density=0.85; M50% Stdev. Solidity=0.04;
Global Stdev. Roundess2= 0.08) is more consistent with the morphology of a control
subject (i.e. Control means of non-standardized Fiber density=0.85; M50% Stdev.
Solidity=0.03; Global Stdev. Roundenss2=0.05). This CLI patient’s muscle has not
degenerated to the extent that the other CLI patients have (i.e. CLI means of nonstandardized Fiber density=0.75; M50% Stdev. Solidity=0.07; Global Stdev. Roundess2=
0.09). Upon examination of this biopsy specimen, the morphology appears to be that of a
control, with a higher fiber density and less variation in roundness and solidity. This
suggests that myofiber morphology alone may not provide sufficient sensitivity to
classify PAD muscle, as a guide for specific treatment of individual patients. It may be
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necessary to incorporate another level of measurement to account for patients that have
normal morphometric indices, but are still CLI.
Our study has limitations. Our data are observational and identify a correlation
between discriminant indices of muscle degeneration and disease stage (claudication and
CLI). However, the data do not establish that the advancing muscle degeneration within a
clinical stage (claudication or CLI) represents progression of disease. Second, the sample
set is not large enough to allow determination of the potential contributions of individual
patient characteristics, such as co-morbid conditions and activity levels, to degree of
muscle degeneration. Third, the control subjects are not precisely matched with PAD
patients on the basis of comorbidities, medications and activity levels. We selected a
control group of similar age and gender composition to the PAD group and included
patients undergoing lower extremity operations for indications other than PAD. All
controls were selected to have normal ABIs at rest and after stress and all led sedentary
lifestyles.
PAD injury could be more precisely classified with addition of other parameters
such as, myofiber oxidative damage, inflammatory cytokines, and mitochondrial
dysfunction. Development and validation of such a panel of tissue-based biomarkers
may produce a powerful classification tool which can: 1) more effectively guide the
treatment of individual patients, with the patients having the most advanced injury being
treated more aggressively, and 2) allow objective determination, at the tissue level, of the
outcomes produced by pharmacologic and surgical interventions. In future studies, these
models which provide scores representing a continuum of myofiber damage may be
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evaluated on the basis of their ability to predict objective, biomechanical indicators of
limb function.
Morphological damage to myofibers can be quantified with small gastrocnemius
samples obtained with minimally invasive needle biopsy, using discriminant modeling. A
discriminant model based on myofiber morphometrics has established a correlation
between advancing muscle degeneration and PAD progression. This model separated
PAD from control patients and provided a grading of muscle degeneration within clinical
stages of PAD. The long-term goal of our work is to develop a comprehensive profile of
quantitative morphometric changes in PAD muscle, which will serve as a guide for more
extensive mechanisms and intervention studies essential for much needed improvement
of diagnosis, staging and treatment of PAD.
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Figure 3.21. A) The sarcolemma labeling provided an outline of each myofiber. B) The
myosin labeling served as a confirmation that a given sarcolemma outline encompassed a
myofiber. C) The final binary segmented image contained the geometry of each
myofiber. Note that myofibers on the edge of the image were removed, as accurate
morphometric parameters could not be extracted from only part of the myofibers.
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Figure 3.22. A) Normal muscle with polygonal shaped myofibers that are uniform in
shape and size, peripherally located nuclei and thin endomysium and perimysium. B) A
specimen of mildly damaged PAD muscle with evidence of mild myofiber atrophy, the
presence of rounded or angular atrophic myofibers. C) A specimen of moderately
damaged PAD muscle with evidence of moderate myofiber atrophy, rounded or angular
atrophic myofibers, occasional internal nuclei, vacuolization and moderate endomysial
fibrosis. D) A specimen of moderately damaged PAD muscle with evidence of severe
myofiber atrophy and enlargement, angular, polygonal or round myofibers, increased
numbers of internal nuclei, and moderate endomysial and perimysial fibrosis.
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Figure 3.23. Patient scores from Model 1 discriminating claudicating patients from CLI
patients, based on mophometric parameters of their gastrocnemius myofibers.
Claudicating patients closer to zero have myofiber morphology that is approaching or is
more similar to the myofiber morphology of CLI patients.
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Figure 3.24. Means of standardized selected parameters for Model 1, used to
discriminate between critical limb ischemia (CLI) and Control/Claudicating patients.
Values are means ± standard error;
*Group means were significantly different using a t-test
*LQ Solidity (P=0.0021) ― (Lower Quartile, i.e. small fibers);
*Global Stdev. Roundness2 (P<0.0001);
*M50% Stdev. Roundness3 (P<0.0001) ― (Middle 50%, i.e. medium size fibers);
*M50% Stdev Solidity (P<0.0001) ― (Middle 50%, i.e. medium size fibers);
*Fiber Density (P=0.0005);
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CLI

Control

A

Myosin image overlaid
with the myofiber outlines
(green) of the segmented
binary image

Binary image of segmented
myofibers (red boundary
encompasses myofibers
plus interstitial tissue)

Sarcolemma image
overlaid with the
myofiber outlines
(green) of the segmented
binary image
Figure 3.25. Fiber density was defined as the area occupied by the myofibers divided by
the area occupied by the myofibers plus interstitial tissue. Panels A & D display myosin
images, with myofiber segmentation overlaid in green. Panel B presents the fiber density
(0.86) of a muscle tissue sample from a control subject, while Panel E presents the fiber
density (0.70) of a muscle tissue sample from a patient with critical limb ischemia (CLI)
and severe myopathic changes. Panels C & F display sarcolemma image, with myofiber
segmentation overlaid in green.
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Figure 3.26. Binary images of segmented myofibers. A) Control. B) Critical limb
ischemia (CLI). C) Control middle 50% based on fiber area (M50% Solidity) and fitted
convex hulls (red). D) CLI middle 50% based on fiber area and fitted convex hulls (red).
M50% CLI fibers exhibit higher variation in solidity (i.e. more concavities) compared to
M50% control fibers. Arrows identify myofibers with reduced solidity.
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Figure 3.27. Means of standardized selected parameters for Model 2, used to
discriminate between Controls and Claudicating patients.
*Group means were significantly different using a t-test
*M50% Stdev. Roundness3 (P=0.0078) ― (Middle 50%, i.e. medium size fibers)
UQ Stdev. Solidity ― (Upper Quartile, i.e. large fibers)
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Table 3.2. Demographics of patients with peripheral arterial disease (PAD) and control
patients.
Control

Claudication

CLI*

19

18

19

64.6 ± 2.6

60.2 ± 1.9

64.0 ± 2.1

16/3

17/1

18/1

Smoking

41.2%

64.7%

78.9%

Obesity

29.4%

23.5%

10.5%

Hypertension

64.7%

88.2%

78.9%

1.08 ± 0.02

0.35 ± 0.06

0.27 ± 0.05

Number of subjects
Mean Age (years)
Gender (male/female)

Ankle brachial index (ABI)
*Critical Limb Ischemia
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Table 3.3. Combining models 1 & 2 training results, classification table.
Predicted Membership

Controls
Actual
Claudication
Membership
CLI*
Total
*Critical Limb Ischemia

Accuracy %

Controls

Claudication

CLI*

Total

8

1

0

9

88.8%

0

9

0

9

100.0%

0

0

10

10

100.0%

8

10

10

28

96.4%
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Table 3.4. Combining models 1 & 2 validation results, classification table.
Predicted Membership
Accuracy %

Actual
Membership

Controls

Claudication

CLI*

Total

Controls

8

2

0

10

80.0%

Claudication

2

7

0

9

77.7%

CLI*

1

0

8

9

88.8%

Total

11

9

8

28

82.1%

*Critical Limb Ischemia
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4.1 ABSTRACT
Peripheral arterial disease (PAD) is a vascular disease characterized by stenosis of the
non-coronary arteries that affects approximately 8 – 10 million Americans. PAD
produces a progressive accumulation of ischemic injury to the limbs that is reflected in a
gradual worsening in the microscopic morphology and oxidative stress in the
gastrocnemius (calf muscle). The objective of this study was to build a comprehensive
discriminant model that incorporated morphometric parameters of myofibers, oxidative
damage in myofibers measured as protein carbonylation, measures of centrally located
nuclei, and measures of clustering micro-fibers to classifying disease severity of PAD.
Biopsies were collected from the gastrocnemius with a Bergstom needle from PAD
patients with claudication (n=19) and critical limb ischemia (CLI; n=20) and control
patients (n=21). High resolution tiled images of 24 adjacent frames of the muscle tissue
specimen were acquired using a 10x objective. The discriminant model, based on
morphometric and oxidative stress parameters, was able to correctly classify clinical
stages of PAD and control patients with an overall accuracy of 83.3% using a crossvalidation procedure. Myofiber morphometrics plus oxidative stress parameters provided
a discriminant model that establishes a correlation between PAD progression and
advancing muscle degeneration. This model effectively separated PAD and control
patients and provided a grading of muscle degeneration within clinical stages of PAD.
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4.2 INTRODUCTION
Peripheral arterial disease (PAD) is a vascular disease characterized by stenosis of
the non-coronary arteries. It is estimated that PAD affects approximately 8 – 10 million
Americans (Norgren et al., 2007). This condition becomes more common as one gets
older and the number of affected Americans is expected to increase with an increase of
the elderly population. In the past, it was presumed that the manifestations of PAD were
solely due to the atherosclerotic blockages and reduced blood flow to the limbs (Pipinos
et al., 2008a). However, the pathophysiology of PAD and its end-organ effects are more
complex than what can be explained by the mismatch of blood flow and oxygen demand
(Hirsch et al., 2006). Literature reports indicate that there is a myopathy that occurs
secondary to the vascular disease (Pipinos et al., 2008a; Pipinos et al., 2008b; Pipinos et
al., 2008c). An increasing number of studies suggest that repeated cycles of ischemia
followed by reperfusion trigger inflammatory responses, compromise cellular
bioenergetics, and generate reactive oxygen species (Pipinos et al., 2008a).
Ambulatory pain caused by inadequate blood flow to the muscles in the lower
extremities is known as claudication (Hirsch et al., 2006). Although patients can
experience leg pain for many other reasons than PAD, a key indicator of PAD is that the
pain is associated with exercise. The exercise induced ischemic conditions cause a
mismatch of oxygen supply and increased demand within the muscle during exercise,
resulting in cramping, pain, fatigue, and discomfort. Upon cessation of exercise and
returning to a resting muscle state, the aching, fatigue, and cramping disappear.
Ultrastructural and biochemical studies demonstrate that the primary organelle damaged
in this process is the mitochondrion (McDermott et al., 2004). Dysfunctional
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mitochondria further lower the already decreased energy levels (associated with
compromised blood supply) in the pathologic muscle and become sources of increasing
levels of reactive oxygen species (ROS) and possibly inducers of apoptosis (McDermott
et al., 2004). Elevated levels of ROS produce oxidative damage to the muscle.
As injury accumulates, the patient’s clinical condition deteriorates from being
asymptomatic to having claudication and then developing critical limb ischemia. Critical
limb ischemia (CLI) is an advanced stage of PAD in which, patients experience pain due
to inadequate blood perfusion while at rest (Hirsch et al., 2006). This condition often
produces non-healing foot ulcers and gangrene, and often leads to amputation.
Progressive accumulation of ischemic injury to the limbs is reflected in a gradual
worsening in the microscopic morphology of the gastrocnemius (calf muscle). Normal
muscle morphology is characterized by polygonal myofibers that are generally uniform in
shape and size, with thin endomysium and perimysium tissue, and peripherally located
nuclei. Moderately myopathic muscle cells generally have an increased variation in
shape and size and begin to develop fiber vacuolization and target lesion with centrally
located nuclei. In severely myopathic myofibers, groups of deteriorating micro-fibers
begin to appear, with myofiber vacuolization, target lesions, centrally located nuclei, and
thicker endomysial and perimysial interstitial tissue that is more fibrotic. Thus,
morphology of myofibers changes during the progression of PAD.
In Chapter 3, we have shown that quantitative morphological parameters of
myofibers in the lower limb musculature, in particular the gastrocnemius, change in a
consistent and predictable manner during the progression of PAD and provided an
objective grading of the disease. The objective of this study is to enhance the
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discriminant model incorporating new variables, such as oxidative damage measured
with protein carbonylation, measures of centrally located nuclei, and measures of
clustering micro-fibers to enhance and create a more comprehensive discriminant model.
Thus, the specific objectives of this study are 1) to characterize peripheral arterial disease
by extracting new variables including centrally located nuclei, clustering of micro-fibers,
and oxidative damage using mechanism-based biomarkers of carbonyl groups, 2) to
develop and validate a discriminant model using morphological and oxidative stress
parameters that classify muscles as control, claudication, and CLI.

4.3 MATERIALS AND METHODS
4.3.1 Tissue Samples
The tissue collection protocol was approved by the Institutional Review Board,
and all subjects gave informed consent. We recruited 19 patients with clinical diagnosis
of claudication, 20 patients with clinical diagnosis of critical limb ischemia (CLI), and 21
controls who did not have PAD. Demographic information, from these patients,
including ABI’s, age, gender, and PAD risk factors are given in Table 4.5. Patient
muscle biopsies, taken from the gastrocnemius were acquired with a Bergstom needle,
fixed in methacarn, and embedded in paraffin. Three 4 µm cross sections, from each
biopsy, were mounted on slides for image acquisition.
4.3.2 Fluorescence Labeling of Tissue Sections
In preparation for labeling sarcolemma, myosin types I and II, protein carbonyls,
and nuclei the slide specimens were deparaffinized with xylene and rehydrated via a
series of ethanol washes and distilled water. The rehydrated slide specimens were then
transferred to a container with 0.01 M citrate buffer (with 0.05% Tween 20; pH 6.0) and
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heated in a microwave set to 65 oC for 10 minutes for epitope recovery and then allowed
to cool for 20 minutes. The slide specimens were soaked in SuperSensitive Wash buffer
(SS; BioGenex Laboratories, Inc., Freemont, CA) for 30 minutes at room temperature,
with stirring. Slides were then prepared for the programmable autostainer by placing a
lipid barrier on the dried areas around the tissue specimens. While applying the lipid
barrier, care was taken to ensure that the tissue specimens were kept moist.
A programmable autostainer (BioGenex i6000; BioGenex Laboratories) was used
to label the sarcolemma, myosin heavy chains, and protein carbonyls. The slide
specimens were washed eight times with SS buffer (4 min. per wash) then native
biotinylation was blocked with avidin (Zymed; Avidin/Biotin blocking kit 00-4303) for
10 minutes, washed two more times with SS buffer (4 min per wash) then treated with
biotin to bind all the sites of avidin. Slide specimens were washed again with SS buffer
two times (4 min per wash) and treated for 5 minutes with a biotinylation buffer 2-(Nmorpholino)ethanesulfonic acid with a pH 5.5 (MES). Subsequently, the slides were
treated with a 5 µM biotinylation solution and incubated at for 1 hour inside a dark slide
box with double distilled water (DdH2O) in the bottom. The biotinylation solution was
prepared from biotin hydrazide (Calibiochem; cat# 203110), dimethylsulfoxide (DMSO;
Sigma cat# 8418-250ML) and MES solution. Biotin hydrazide reacts specifically with
carbonyl groups of aldehydes and keytones, forming hydrozone bonds and converting
carbonyl groups to biotin groups. Slide specimens were then placed in a glass container
filled with phosphate buffered saline (PBS) and stirred with a stir bar for 10 minutes.
The slides were then placed in a 15 mM cyanoborohydride (Aldrich cat#156159-10G)
solution and incubated at room temperature for 30 minutes to stabilize the hydrazone
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bonds. Slide specimens were then placed in a glass container filled with PBS solution
and stored overnight in the refrigerator at 5 oC. After overnight incubation, slide
specimens were loaded into the autostainer and were washed two times with SS buffer (4
min. per wash) then labeled for 30 minutes with streptavidin coupled with Alexa Fluor
488 (Life Technologies-Molecular Probes; S32354) which binds to the biotinylated
carbonyls allowing detection and quantification of protein carbonylation. The slide
specimens were washed two times with SS buffer (4 min per wash) then blocked with
10% goat serum for 20 minutes. Subsequently, the slides were treated with a mixture of
anti-Type I myosin (Sigma-Aldrich, St. Louis, MO; M8421, clone NOQ7.5.4D) and antiType II Myosin (Sigma-Aldrich; M4276, clone MY-32) antibodies, for 90 minutes.
Slides were treated with primary antibody or isotype control for 90 minutes, then washed
two times with SS buffer (4 min. per wash), followed by a labeling of goat anti-mouse
IgG Alexa Fluor 594 conjugate (Life Technologies-Molecular Probes; A11032) for 30
min. The slide specimens were washed two more times with SS buffer (4 min per wash)
and then treated for 1 hour with wheat germ agglutinin-Alexa Fluor 647 to label the
sarcolemma (Life Technologies-Molecular Probes, Grand Island, NY; W11263). Treated
slides were washed two times with SS buffer. Finally, ProLong Gold antifade medium
with DAPI nuclear stain (Life Technologies-Molecular Probes; P36931) was applied to
the labeled specimens and covered with a coverslip. The slides were stored at room
temperature for 24 hours, sealed with clear lacquer, and then kept at 5 oC for subsequent
fluorescence imaging.
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4.3.3 Fluorescence Image Acquisition
Gray scale (12-bit) images (1344 × 1044 pixels) of gastrocnemius myofibers were
acquired with a CCD camera (Orca ER C4742-95; Hamamatsu Photonics, Bridgewater,
NJ), a Leica microscope (DMRXA2; North Central Instruments, Plymouth, MN)(10×
objective; 0.51 µm/pixel), with an automated stage, and Image-Pro® Plus software.
Excitation energy was delivered with a 150 W HgXe lamp (Hamamatsu Photonics).
Images were collected from 24 microscope fields (1344 × 1044 pixels) adjacent to
each other (4 columns × 6 rows) and tiled resulting in a large high-resolution tiled image
(5376 × 6144 pixels) of each of three slides per patient. At each field of view, images
were collected in fluorescence channels corresponding to each fluorophore; 1) excitation
495 nm and emission at 519 nm (Alexa Fluor 488) for protein carbonylation imaging
shown in Figure 4.28; 2) excitation at 590 nm and emission at 617 nm (Alexa Fluor 594)
for myosin types I and II imaging shown in Figure 4.29; 3) excitation at 650 nm and
emission at 668 nm (Alexa Fluor 647) for imaging the sarcolemma Figure 4.30; and 4)
excitation at 675 nm and emission at 694 nm (DAPI) for imaging the muscle nuclei,
shown in Figure 4.31.
4.3.4 Image Processing
To extract morphometric parameters for each myofiber and measure protein
carbonyl content, the individual myofibers were isolated by segmentation of the
fluorescence image. Image segmentation was done with a custom algorithm written in
MATLAB (R2009a Mathworks Inc. Natic, MA.), which was based on simple
thresholding, edge detection, erosion, dilation, and a set of heuristics. Labeled
sarcolemma (Figure 4.30) provided an outline of each myofiber, while labeled myosin

113
(Figure 4.29) confirmed that a given outline encompassed a myofiber, as opposed to a fat
cell or other element of the inter-myofiber space. Myofibers on the edge of the image
were omitted from the final binary segmented image, as accurate morphometric
parameters could not be extracted from only part of fibers. The final binary segmented
image contained the geometry of each individual myofiber, as displayed in Figure 4.32.
Figure 4.33 displays a flow chart of the methodology used to segment the
individual myofibers in the image. Any errors in image segmentation usually came from
images that had poor labeling or non-uniform labeling. Occasionally, the labeled
sarcolemma did not form a complete boundary around the myofiber. Likewise, on
occasion the myosin labeled image had dark areas where the Alexa Fluor did not label
very well. So in some cases the myosin labeled image produced a better myofiber
segmentation and in other cases the sarcolemma image produced better myofiber
segmentation. Therefore, to achieve the best automated image segmentation, the
segmentation process was performed on both the myosin and sarcolemma labeled images
separately and then presented to a heuristic algorithm that chose the best of each to
produce a final segmented image.
4.3.5 Heuristic rules to improve myofiber image segmentation
Figure 4.34 presents some common image segmentation errors (circled in red)
that were encountered due to non-uniform labeling of the sarcolemma or myosin. The
heuristic algorithm evaluated each individual myofiber from both the myosin
segmentation and the sarcolemma segmented images and selected the best based on a set
of heuristic rules that produced the most accurate automated myofiber segmentation. The
automation of this segmentation process significantly reduced the time that would have

114
been required to manually segment each image, while still preserving accurate myofiber
segmentation. In Figure 4.34 the green circled areas, represent the correct segmentation
and the fibers that were used to build the final segmented image. Red circled areas (in
Figure 4.34) represent segmentation errors that were recognized by the heuristic
algorithm and therefore removed from the final segmented image. Heuristic rule #1
evaluated whether or not a given object in the sarcolemma image was in fact a myofiber.
This was done by comparing the pixel value at the same location on the corresponding
myosin labeled image segmentation. If there was no myosin present at that location then
that object in the sarcolemma image was not a myofiber and therefore removed from the
final segmented image. Heuristic rule #2 preserved narrow myofibers from being split
during the erosion and dilation processes. This type of error usually occurred during
segmentation of narrow myofibers while using the sarcolemma image. Hence the rule
would compare the sarcolemma segmentation with the myosin segmentation, specifically
looking at myofibers with small minor axes and judge whether or not the narrow fiber
was erroneously split into two myofibers. Heuristic rule #3 looked for “joint” myofibers
that were connected, but should have been separated. These “joint” fibers were identified
when one fiber would occupy the same corresponding space of two or more fibers in the
other segmented image. If a heavy erosion turned the one fiber into three then it was
confirmed that it was indeed three fibers, whereas, if one fiber remained as one fiber even
after performing a heavy erosion then it was confirmed that it was indeed one fiber and
the other segmented image erroneously produced three segmented fibers. Based on this
heuristic, “joint” myofibers were found and removed from the final segmented image.
Heuristic rule #4 identified fibers that did not segment well during thresholding, due to
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non-uniform labeling and selected the correctly segmented fiber for the final segmented
image. This type of error generally occurred during segmentation with the myosin
image. Therefore, based on a measure of solidity and a comparison of the corresponding
myofiber within the sarcolemma segmented image, poor image segmentation was
identified and a judgment was made to keep the sarcolemma segmentation for that
myofiber. Heuristic rule #5 preserved the shape of smaller fibers, by recognizing that
with the sarcolemma image small fibers, often were lost during segmentation, and
therefore these were selected from the segmented, myosin image. Myofiber image
segmentation was considerably improved and the time to segment the images was
significantly reduced by automating the segmentation process, based on these heuristic
rules.
4.3.6 Oxidative Damage and Morphometric Measures
Morphometric variables as well as oxidative damage variables were measured
from each myofiber and the averages and standard deviations were used as inputs to a
discriminant model to classify PAD and control muscle. Protein carbonylation in
myofibers was measured as the average and standard deviation in pixel value intensity
from myofiber images captured using quantitative fluorescence microscopy of
biotinylated carbonyls coupled with fluorphor. This measure represented oxidative
damage in the muscle tissue. In addition, multiple morphometric features, as described in
Chapter 3, were measured from each myofiber as well. The morphometric features
included: 1) myofiber cross-sectional area, calculated as the number of pixels enclosed
within a segmented myofiber, 2) lengths of major and minor axes of the myofiber, 3)
myofiber perimeter, measured as the number of pixels on the boundary of the myofiber,
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4) equivalent diameter, 5) three measures of roundness (Chapter 3), 6) myofiber solidity,
defined as the area of the myofiber divided by the area of a fitted convex hull and 7)
myofiber eccentricity. Eccentricity is a measure of how much a shape deviates from a
circle and was measured by calculating the ratio of distance between foci, Equation (4.1),
to major axis, as shown in Equation (4.2). If the myofiber was a perfect circle the
eccentricity would equal to zero, whereas, if the myofiber was an elongated ellipse the
eccentricity approached a value of one. Fiber density was measured as well, defined as
the area occupied by the myofibers divided by the area occupied by the myofibers plus
interstitial tissue, as described in Chapter 3.
√( )

( )

(4.1)

where, x is the major axis and y is the minor axis

(4.2)
Further, clustering of degenerating myofibers was measured as well; using a
custom density based clustering routine. The density based clustering routine identified
fiber clustering by examining the proximity (within 30 pixels of each other) of smaller
myofibers (fiber area ≤ 4000 pixels), as shown in
Figure 4.35. If the fibers that had a fiber area ≤ 4000 pixels were within 30
pixels of each other, they were grouped as a cluster. We will refer to these small
myofibers that appear in clusters of degenerating myofibers as micro-fiber clusters.
Additional variables were extracted from the micro-fiber cluster analysis, such as; 1)
number of fibers per cluster, 2) average fiber area per cluster, 3) number of clusters per
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tissue sample, and 4) the average distance from fiber centroid to cluster centroid was
calculated.
Finally, a quartile analysis was performed on each tissue specimen, by which the
myofibers were separated into three groups based on cross-sectional fiber area, the lower
quartile (small fibers) denoted as ‘LQ’, the middle two quartiles (medium size fibers)
denoted as ‘M50%’, and the upper quartile (larger fibers) denoted as ‘UQ’. Quartile
analysis was performed so that morphometric features within the lower and upper
quartiles would not be lost in the average of the global morphometric measurements. The
mean and standard deviation of oxidative damage and morphometric variables for all
myofibers and for myofibers in quartiles of cross-sectional area and fiber density were
used to represent each patient. Thus, a total of 93 variables for the 60 patients were used
to build a classification model that discriminates PAD and control muscle, and provides
an objective grading of disease.

4.3.7 Data Analysis
A data preprocessing step was performed in order to check and meet discriminant
model assumptions. In addition, the multivariate data were standardized (mean centering
of each variable followed by normalization by the corresponding standard deviation of
that variable) to remove units and put each variable on the same scale. Variable
contribution was analyzed using a stepwise selection procedure (Klecka, 1980; Jennrich
et al., 1977) in SAS 9.2 (The SAS Institute, Cary, NC.). Stepwise selection uses both
forward selection and backward elimination procedures while evaluating the contribution
to the discriminatory power of the model (Costanza and Afifi, 1979).
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Linear discriminant analysis was used to create rules that discriminate PAD
patients and controls based on morphometric variables. The discriminant analysis was
performed in two stages using two models. The first model (Model 1) was designed to
discriminate patients with CLI from the group of control and claudicating
(control/claudicating) patients. The second model (Model 2) was designed to discriminate
control patients from the claudicating patients.
Seven variables were selected for discriminant Model 1, namely, standard
deviation of the myofiber diameter from the lower quartile (LQ Stdev. Diameter),
standard deviation of myofiber perimeter from the lower quartile (LQ Stdev. perimeter),
average myofiber area from myofibers within clusters of micro-fibers (CFA), the standard
deviation of carbonyl pixel intensities (Stdev. Carbonyl), from the middle two quartiles
standard deviation of myofiber solidity (M50% Stdev. Solidity), fiber density, and average
myofiber solidity from the lower quartile (LQ Solidity).
Model 1 was designed to discriminate CLI patients from the controls and
claudicating patients. All samples that were classified into the control/claudication group
by Model 1 were passed on to the next stage for analysis by Model 2; which
discriminates control and claudicating patients. Six morphometric variables were
selected for Model 2, namely, the global standard deviation of myofiber perimeter (GL
Stdev. Perimeter), average myofiber solidity from the lower quartile (LQ Solidity),
average carbonyl pixel intensity, the standard deviation of myofiber major axis from the
upper quartile (UQ Stdev. Major Axis), standard deviation of myofiber diameter from the
upper quartile (UQ Stdev. Diameter), and the standard deviation of myofiber eccentricity
from the upper quartile (UQ Stdev. Eccentricity).
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4.4 RESULTS AND DISCUSSION
Figure 3.2 from Chapter 3 exhibit the progressive accumulation of injury to the
muscle of PAD patients ranging from mild, to moderate, to severe morphometric changes
in the myofibers. In this study, we evaluated the hypotheses that morphometric
determinants and oxidative damage of myofibers, in needle biopsies of the
gastrocnemius, discriminate PAD patients from controls and quantify disease severity.
Model 1 is a mathematical rule derived using linear discriminant analysis to separate CLI
patients from control and claudicating patients.
Model 1: Linear discriminant Model 1 is given in Equation (4.3).
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All patients classified into the Control/Claudicating group by Model 1 were then passed
on to Model 2 which was designed to discriminate between controls and claudicating
patients. Model 2 is a mathematical rule derived using linear discriminant analysis to
separate patients from control and claudicating patients.
Model 2: Linear discriminant Model 2 is given in Equations (4.4).
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Model 1 was able to correctly classify 17 of 20 CLI patients yielding an 85.0% accuracy
and correctly classified 36 out of 40 Control/Claudicating patients using a full crossvalidation procedure. The 36 patients that Model 1 classified as Control/Claudicating
were then passed on to Model 2 which was able to correctly classify 18 out of 21 control
patients (85.7%) and correctly classify 15 out of 15 claudicating patients (100%). Table
4.6 combines the classification and misclassification results from both models into a
confusion matrix. After combining the results from both models, 85.7% of control
patients, 78.9% of claudicating patients, and 85.9% of CLI patients were correctly
classified yielding an overall accuracy of 83.3%.
An independent t-test was used to test for significant differences in group means
of the standardized variables used in Model 1 (Figure 4.36), where a p-value < 0.05 was
considered significant. Again, as was found in the earlier study performed in Chapter 3,
Fiber density, M50% Stedev. Solidity, and LQ Solidity were all found to be significantly
different between CLI patients and controls/claudicating patients with p-values of
P=0.0017, P=0.0039, and P=0.0195 respectively. These results indicate that CLI patients
have lower fiber density, higher variation in solidity within medium size fibers, and are
less solid within smaller fibers when compared to control and claudicating patients. Note
that the previous study performed in Chapter 3 had a smaller data set of approximately
15,000 myofibers, while this current data set was about 5 times larger, examining
approximately 165,000 myofibers. Further, in this larger data set new variables including
oxidative damage measurements, centrally located nuclei, and micro-fiber clustering
were incorporated as well. Thus, using this larger data set additional new morphometric
parameters were found to be useful in rebuilding the discriminant model, while some of
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the variables found in Chapter 3 were no longer included in the model. New parameters
found to be important for this model included LQ Stdev. Diameter, LQ Stdev. Perimeter,
and average fiber area among micro-fiber clusters (CFA) with p-values P<0.0001,
P=0.0012, and P<0.0001 respectively. These variables reveal that CLI patients have less
variation in diameter and perimeter among smaller fibers (i.e. lower quartile). These
results make sense, as CLI patients tend to have more degenerating myofibers and
degenerating myofibers tend to fall into the lower quartile in terms of fiber area.
Therefore, the small degenerating myofibers were usually round and more uniform.
Further, CLI patients had more micro-fiber clustering than control and claudication
patients. Note, in the earlier study (Chapter 3) micro-fiber clustering was measured as
well, but not selected by the model. This suggests that the low-resolution images (i.e.
randomly captured images from 5 locations on the tissue specimen) was not able to pick
up micro-fiber clustering effectively. Whereas, within this study the high-resolution tiled
images were able to effectively capture this variable. Another variable of importance was
the variation of oxidative damage (Carbonyl Stdev.) with a p-value of P=0.0531 was very
close to the significant level and thus was still an important variable. This measure of
oxidative damage to the muscle suggested that CLI patients have a larger variation of
protein carbonylation compared to control and claudicating patients.
In Model 2, which was designed to discriminate claudicating and control patients,
the Global Stdev. Perimeter and UQ Stdev. Diameter were significantly different between
control and claudicating patients with p-values of P=0.0356 and P=0.0422 respectively.
In general, control patients had a higher variation in perimeter globally and higher
variation in diameter among the larger fibers than claudicating patients.
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Among the predictors in Model 1, variation in the diameter of small fibers (LQ
Stdev. Diameter), variation in the perimeter of smaller fibers (LQ Stdev. Perimeter),
clustering of micro-fibers (CFA), and variation in protein carbonyls (Stdev. Carbonyl)
had the most influence in the model, based on the coefficients in the model. Lower
values in the variables LQ Stdev. Diameter and LQ Stedev. Perimeter in CLI patients
indicate that smaller degenerating myofibers are more consistent in diameter and
perimeter than the smaller myofibers found in control and claudicating patients. Higher
CFA measures in CLI patients reflect increased levels of localized clustering of
neighboring, small degenerating myofibers which is sometimes referred to as group
atrophy. Higher variation in protein carbonyls (Stdev. Carbonyl) reflects more oxidative
damage in CLI patients and is in agreement with previous research (Pipinos et al., 2008a)
demonstrating that PAD muscle has mitochondrial dysfunction. Variables with the
greatest influence in Model 2 included variation in the major axis of the larger fibers (UQ
Stdev. Major Axis), variation in perimeter as a global measurement (Global Stdev.
Perimeter), and variation in solidity of smaller fibers (LQ Solidity).
This study used morphometric determinants and biochemical (mechanisms-based
biomarker expressions of oxidative stress) of myofibers, in needle biopsies of the
gastrocnemius, to build a more comprehensive discriminant model. The discriminant
model, based on the morphometrics and oxidative stress in muscle tissue, was able to
discriminate clinical stages of PAD and controls with an overall accuracy of 83.3%.
When compared to the results obtained in Chapter 3, which was able to classify clinical
stages of PAD and control patients with 82.1% accuracy, the results are repeatable.
However, there are some noticeable differences in the selected variables between the
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model developed in this study compared to the model created in Chapter 3. Likely the
model created in this study is a more complete and accurate representation of the muscle
damage in PAD patients. The model created in Chapter 3 was performed on a much
smaller data set sampled from 5 regions of the muscle tissue that were selected manually,
whereas the model created in this study was built on a larger data set of high resolution
tiled images incorporating large portions of the muscle tissue. Further, the model in this
study incorporated oxidative stress variables.

4.5 CONCLUSION
PAD produces a progressive accumulation of ischemic injury to the limbs. This
ischemic injury is reflected in a gradual worsening in the microscopic morphology and
oxidative stress in the gastrocnemius (calf muscle). The discriminant model, based on
morphometric and oxidative stress parameters, was able to correctly classify clinical
stages of PAD and control patients with an overall accuracy of 83.3% using a crossvalidation procedure. When compared to the previous study carried out in Chapter 3
these methods for quantifying muscle damage appear repeatable. However, the model
created in this study is likely the more complete model that included biochemical
oxidative damage and morphological parameters. The discriminant model may be used
as a complimentary tool to traditional diagnosis/monitoring criterion, providing objective
criteria for therapeutic interventions. The ability to quantify oxidative stress and
characterize the extent of muscle damage due to the disease may provide physicians with
objective measures to diagnose, monitor muscle degeneration, and aid in the development
of patient-specific treatments.
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Figure 4.28. Protein carbonyl labeled image. High resolution tiled image (5376 × 6144
pixels) of ~1000 myofibers. Spatial calibration reference bar is 200 µm.

125

Figure 4.29. Myosin labeled image. High resolution tiled image (5376 × 6144 pixels) of
~1000 myofibers. Spatial calibration reference bar is 200 µm.
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Figure 4.30. Sarcolemma labeled image. High resolution tiled image (5376 × 6144
pixels) of ~1000 myofibers. Spatial calibration reference bar is 200 µm.
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Figure 4.31. Myofiber nuclei labeled image. High resolution tiled image (5376 × 6144
pixels) of nuclei from ~1000 myofibers. Spatial calibration reference bar is 200 µm.
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Figure 4.32. Binary myofiber segmentation image. High resolution tiled image (5376 ×
6144 pixels) of ~1000 segmented myofibers.
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Figure 4.33. Flow chart of myofiber segmentation process using both myosin labeled
image and sarcolemma labeled image.
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Figure 4.34. Examples of myofiber segmentation errors and heuristic rules used to
improve automated myofiber segmentation. Green circled areas represent the correct
segmentation and the fibers that were used to build the final segmented image. Red
circled areas represent segmentation errors that were recognized by the heuristic
algorithm and therefore removed from the final segmented image. 1) Not a myofiber
check, 2) Split narrow myofibers check, 3) Joint myofibers check, 4) Poor segmentation
due to non-uniform labeling check, 5) Preserve shape of small fibers during erosion and
dilation check.
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Micro-fiber clustering
Figure 4.35. Micro-fiber clustering or group atrophy events were identified using a
density based clustering routine and statistical measures were acquired to quantify
clustering of small degenerating myofibers.
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Figure 4.36. Means of standardized selected variables for Model 1, used to discriminate
between critical limb ischemia (CLI) patients from Control and Claudicating patients.
Values are standardized group means ± standard error
*Group means were significantly different using a t-test
*LQ Stdev. Diameter (P<0.0001) – (Lower Quartile, i.e. small fibers);
*LQ Stdev. Perimeter (P=0.0012);
*CFA (P<0.0001) – (average cluster fiber area);
Carbonyl Stdev. (P=0.0531);
*M50% Stdev. Solidity (P=0.0039) – (Middle 50%, i.e. medium size fibers)
*Fiber Density (P=0.0017);
*LQ Solidity (P=0.0195);
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Figure 4.37. Means of standardized selected parameters for Model 2, used to
discriminate between Controls and Claudicating patients.
*Group means were significantly different using a t-test
*Global Stdev. Perimeter (P=)
*UQ Eccentricity ― (Upper Quartile, i.e. large fibers)
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Table 4.5. Demographics of patients with peripheral arterial disease (PAD) and control
patients.

Number of subjects
Mean Age (years)
Gender (male/female)

Control

Claudication

CLI

21

19

20

63.8±11.1

63.2±8.7

61.5±7.0

17/4

19/0

18/2

Table 4.6. Discriminant model classification table cross-validation results.
Predicted Membership
Accuracy %

Actual
Membership

Controls

Claudication

CLI*

Total

Controls

18

3

0

21

85.7%

Claudication

0

15

4

19

78.9%

CLI

0

3

17

20

85.0%

Total

18

21

21

60

83.3%

* Critical Limb Ischemia
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5.1 ABSTRACT
Peripheral arterial disease (PAD), characterized by abnormal narrowing of the noncoronary arteries, produces a considerable public health burden. PAD produces a
progressive accumulation of ischemic injury to the lower limbs that is reflected in altered
metabolic processes, damaged organelles, and compromised bioenergetics. The objective
of this study was to correlate PAD patient blood flow (Ankle Brachial Index) with Raman
spectral signatures of their muscle biochemistry and identify spectral biomarkers that
characterize muscle damage. We collected muscle tissue biopsies of the gastrocnemius
(calf muscle) from 5 patients with clinically diagnosed critical limb ischemia (CLI), 5
patients with clinically diagnosed claudication, and 5 control patients who did not have
PAD. A partial least squares regression (PLSR) model was able to predict patient ABI’s
with a correlation coefficient of 0.99 during training and a correlation coefficient of 0.85
using a full cross-validation. When using the first three PLS factor scores in combination
with linear discriminant analysis, the discriminant model was able to correctly classify
the control, claudicating, and CLI patients with 100% accuracy, using a full cross
validation procedure. In this study we have demonstrated that Raman spectroscopy can
be a powerful bioanalytical tool that is capable of detecting and correlating biochemical
composition with patient ABI’s and discriminating PAD clinical diagnosis. Raman shifts
that are related to muscle biochemistry and patient ABI’s have been identified. Raman
spectroscopy provides novel spectral biomarkers the may complement existing diagnosis
and treatment monitoring methods for peripheral arterial disease.
Keywords: Raman spectroscopy; Peripheral arterial disease; Partial least squares
regression; Linear discriminant analysis; Muscle biochemistry
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5.2 INTRODUCTION
Peripheral arterial disease (PAD), characterized by abnormal narrowing of the
non-coronary arteries, produces a considerable public health burden affecting 12% to
20% of Americans above the age 65 (Mahoney et al., 2010; Mahoney et al., 2008; Roger
et al., 2011). The pathophysiology of PAD is complex and involves changes occurring
on multiple levels, such as reduced blood flow, altered metabolic processes, and skeletal
muscle degeneration (Pipinos et al., 2008b; Pipinos et al., 2008c; Hedberg et al., 1988;
Marbini et al., 1986). PAD produces a progressive accumulation of ischemic injury to
the lower limbs that is reflected in a gradual worsening in the microscopic morphology of
the gastrocnemius (Hedberg et al., 1988; Pipinos et al., 2008a). Limb hemodynamics,
such as Ankle Brachial Index (ABI) is the current gold standard in diagnosing and
monitoring treatment interventions of PAD. ABI’s are measured as the ratio of systolic
pressure in the ankle to that in that in the arm. Occlusions of the arteries supplying
oxygen to the legs cause low ankle blood pressure and yielding a low ABI which is the
clinical hallmark of PAD. The presence of PAD is defined by ABI values of < 0.90, with
values 0.90 – 1.0 considered in the normal range. Other advanced methods such as,
ultrasonography, venous plethysmography, angiography (x-ray) or (MRA), have been
employed to characterize PAD based on monitoring blood flow. However, all these
methods have limitations in monitoring progression and regression of PAD because there
is a need to measure more than just abnormal blood flow. There is a fundamental gap in
monitoring muscle degeneration progression and regression before and after vascular
reperfusion surgeries. It is also critical to measure the skeletal muscle effects (i.e.
myopathy) due to atherosclerosis in addition to measuring the blood flow (Kramer,
2007).
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Recent ultrastructural and biochemical studies have begun to characterize the
myopathy that occurs secondary to the vascular disease. These studies have
demonstrated that repeated cycles of ischemia followed by reperfusion, occurring with
basic daily activities, initiate inflammatory pathways and induce the generation of
reactive oxygen species (ROS) in the PAD muscle, causing oxidative damage
(McDermott et al., 2004).
Raman spectroscopy is a label-free analytical tool that uses the scattering
properties of light to characterize molecular vibrations within a tissue sample, producing
a molecular fingerprint. Raman spectroscopy provides information-rich molecular
profiles and has potentially important clinical applications for real-time in situ evaluation
of living tissues (Hanlon et al., 2000). Raman spectral analysis has been conducted to
characterize several diseases in biological tissues, including, bronchial tissue, brain
tissue, stomach ulcers, and breast tissue (Bonifacia et al., 2010; Nijssen et al., 2002;
Koljenovic et al., 2004; Kirsch et al., 2010). Other investigations have demonstrated that
Raman spectroscopy is capable of identifying and constructing chemical maps of
subcellular structures such as, the nucleus, cytoplasm, and mitochondria (Miljković et al.,
2010; Bonnier et al., 2010). Applications of Raman spectroscopy have been further
broadened by making use of metallic nanostructured surfaces to increase the Raman
scattering signal by multi-fold, referred to as surface-enhanced Raman spectroscopy
(SERS) (Blackie et al., 2009).
The objective of this study is to correlate patient blood flow (determined as ABI)
with Raman spectral signatures of their muscle and identify spectral biomarkers that
characterize altered muscle biochemistry in patients with PAD. Our central hypothesis is
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that surface-enhanced Raman spectroscopy (SERS) signatures from human biopsy
samples (gastrocnemius muscle) mounted on a nanostructured gold-slide can be used to
predict patient ABIs and characterize the muscle damage caused by PAD. The rationale
that underlies this research is that a molecular profile which correlates with ABI and
clinical stages of disease may provide useful biochemical information to identify factors
that may regulate or may be precursors to muscle damage and may facilitate the
development of treatment interventions in human muscle repair.

5.3 MATERIALS AND METHODS
5.3.1 Tissue Samples
The tissue collection protocol was approved by the Institutional Review Board,
and all subjects gave informed consent. We collected muscle tissue biopsies of the
gastrocnemius (calf muscle) from 5 patients with clinically diagnosed critical limb
ischemia (CLI; ABI<0.4), 5 patients with clinically diagnosed claudication (0.4 ≤ ABI ≤
0.9), and 5 control patients (ABI>.9) who did not have PAD. Demographic information,
from these patients, including ABI’s, age, gender, and PAD risk factors are given in
Table 5.7. The biopsies were acquired with a Bergstom needle, fixed in methacarn, and
embedded in paraffin. Two 4µm cross sections, from each biopsy, were mounted on
slides for Raman spectra acquisition. Prior to Raman spectra acquisition, the slide
specimens were deparaffinized with xylene and a series of ethanol washes and allowed to
air dry.
5.3.2 Surface Enhanced Raman Spectroscopy (SERS)
All tissue specimens were mounted on nanostrucutured gold slides
(AU.1000.ALSI; Platypus Technologies, Madison, WI.) for surface enhanced Raman
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spectroscopy. Additionally, 2 control and 2 PAD tissue specimens were mounted on
glass slides for comparison to the SERS signal. The inVia Raman microscope
(Renishaw, Gloucestershire, UK) spectral imaging system was used to acquire Raman
spectra and surfaced-enhanced Raman spectra of human muscle biopsy specimens. This
system is a high-sensitivity research grade system that supports multiple excitation lasers
and allows acquisition of information-rich spectral images.
Raman spectral signatures were collected within the finger print region (303 −
1901 cm-1) using a 514 nm excitation laser, with a 50X magnification objective. The
tissue was photo-bleached for 60 seconds and then the spectrum was collected with a 10
second exposure time. From each tissue specimen, approximately 10 spectra were
collected from 10 individual myofibers and then averaged (after data preprocessing) to
represent the tissue specimen.
5.3.3 Data preprocessing
Data preprocessing of the raw surface-enhanced Raman spectra included baseline
correction and normalization techniques. The Raman spectra were baseline corrected
using the Vancouver Raman algorithm (Zhao et al., 2007) with a five point boxcar
smoothing and a 5th order polynomial fit, shown in Figure 5.38. The Vancouver Raman
algorithm is a robust iterative modified multi-polynomial fitting algorithm that removes
intrinsic autofluorescence background signals and improves signal to noise ratios (Zhao
et al., 2007; Lieber and Mahadevan-Jansen, 2003; Beier and Berger, 2009; Afseth et al.,
2006). Following baseline correction, the spectra were normalized using the standard
normal variate (SNV) technique. SNV normalization is a common mathematical
transformation for spectral data and is designed to remove multiplicative error and
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preserve the linear relationship between the spectral signal and sample concentration
(Rinnan et al., 2009; Barnes et al., 1989).
5.3.4 Model development
A partial least squares regression (PLSR) model was developed using the entire
spectral region from 303 cm-1 − 1901 cm-1 to predict patient ABI. The PLSR algorithm
combines techniques used in principal component analysis (PCA) and multiple linear
regression and attempts to quantify the strength of the relationship between the response
variable and a set of predictor variables (Geladi and Kowalski, 1986). PLSR searches for
principal components (called factors) that are orthogonal to each other and tries to relate
them to the response variable. The variation present in the response variable can be
summarized into a few PLS factors. The first PLS factors that explain the most variance
in the data can then be used to build a regression model. An analysis of the β-coefficients
on the partial least squares regression model can identify which variables had the most
weight in the predictive PLSR model. A full cross validation procedure was performed
on the data set to evaluate the performance of the predictive model.
In addition to the PLSR model, a discriminant model was developed as well using
the PLS factor scores from the PLSR model to classify patient’s as control, claudicating,
or CLI. The use of discriminant analysis in combination with PLS factor scores is a
common multivariate statistical method to establish a mathematical rule that separates
two or more classes from each other (Anderson, 1984; Fisher, 1936). Once the
discriminant model has been derived it can be used to classify new observations (Johnson
and Wichern, 2007). The discriminant model performance was evaluated with a full
cross validation procedure as well.
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5.4 RESULTS
5.4.1 Surface enhanced Raman spectroscopy
Figure 5.39 demonstrates the difference between standard Raman spectroscopy
(n=143 myofibers mounted on glass slides from 2 control and 2 PAD tissue specimens)
and surface-enhanced Raman spectroscopy (n=150 myofibers mounted on nanostructured
gold-slides from 2 control and 2 PAD tissue specimens). The Raman Effect deals with
the inelastic scattering of light, resulting in a scattered photon that has a shift in frequency
from the excitation laser. In general, Raman scattering produces a very weak signal due
to the fact that only a small fraction, approximately 1 in 10 million, of photons will
exhibit the Raman Effect. Surface enhanced Raman spectroscopy (SERS) is a surface
sensitive technique that can enhance the Raman signal by 10 fold (Blackie et al., 2009).
From Figure 5.39 it is readily apparent that surface-enhanced Raman spectroscopy
(SERS) enhances the spectral signature of myofibers mounted on nanostructured goldslides when compared to myofibers mounted on glass slides. The tissue mounted on the
nanostructured gold-slides produced sharper and more intense Raman peaks. Hence
further analyses were performed based on tissue specimens mounted on gold-slides for
surface-enhanced Raman spectroscopy.
5.4.2 Partial least squares regression and discriminant analysis
Figure 5.40 presents the averaged baseline-corrected SNV SERS for control,
claudicating, and CLI patient specimens, which were used to develop the PLSR model.
Nearly all of the variance (99%) in the response variable (patient ABI) was accounted for
by the first six PLS factors, as shown in Figure 5.41. Using the first six PLS factors, the
PLSR model was trained and the predictive performance was evaluated using a full cross-
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validation procedure. The PLSR model was able to predict patient ABIs with a
correlation coefficient of 0.99 during training and a correlation coefficient of 0.85 using a
full cross-validation, show in Figure 5.42. The β-coefficients for the PLSR model are
presented in Figure 5.43, which can be used to identify key wavenumbers that influence
the PLSR model.
Further, a plot of the first three PLS factor scores (Figure 5.44) displays clear
separation of controls, claudicating, and CLI patients. When using the first three PLS
factor scores in combination with linear discriminant analysis a discriminant model is
able to correctly classify the control, claudicating, and CLI patients with 100% accuracy.
Evaluating the discriminant model performance and stability using a cross-validation
procedure also yielded 100% accuracy in patient classification. Table 5.8 presents the
classification table for the discriminant model cross validation results. The combination
of PLS factors 1 and 2 (Figure 5.44A) clearly group and separate control patients from
claudicating and CLI patients, while, PLS factor 3 (Figure 5.44B) clearly separates
claudicating patients from CLI patients.

5.5 DISCUSSION
Raman spectroscopy is a powerful noninvasive, optical tool capable of detecting
biochemical composition within biological tissue, without the use of labeling procedures.
In this study, we have demonstrated that Raman spectroscopy is capable of predicting
patient ABIs based on the biochemical fingerprint of PAD muscle tissue. The PLSR
model was able to correlate Raman spectral information with patient ABIs with a high
level of correlation (R-value=0.85). Moreover, when combining PLS factor scores with
discriminant analysis the model is able to correctly classify patients with 100% accuracy.
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To our knowledge, this is the first study to produce a Raman spectral profile of human
PAD muscle tissue. Further, very few studies, using other techniques, have been able to
correlate patient ABIs with biochemical or limb functional parameters. This study is
novel because it characterizes PAD muscle biochemistry and correlates it to patient
ABI’s in a manner that has never been done before.
An examination of the PLS regression β-coefficients (Figure 5.43) gives an
indication of which wavenumbers had the most important impact on predicting patient
ABIs. From Figure 5.43, it can be seen that wavenumbers 519, 524, 718-722, 752-755,
and 1179 cm-1 had the largest beta coefficients and thus indicate that these are key Raman
spectral bands that reflect the patient ABIs. The band occurring at 519 cm-1 was
attributed to phosphatidylinositol, a phospholipid component of the cell membrane of
eukaryotic cells (Movasaghi et al., 2007; Lakshimi et al., 2002). On average, this band
had a higher intensity for CLI patients than control patients and a negative relationship
with ABIs. The band appearing at 524 cm-1 was assigned to both the S-S disulfide
stretching in proteins and phosphatidylserine (Movasaghi et al., 2007; Stone et al., 2004).
Phosphatidylserine is also a phospholipid component of the cell membrane that is usually
present on the inner leaflet of the bilayer, but becomes exposed at the cell surface during
apoptosis (Verhoven et al., 1995). On average, this band had a higher intensity for CLI
patients than controls and may indicate higher levels of apoptosis occurring in advanced
stages of muscle degeneration. The 718 cm-1 band correlates with C-N vibrational
stretching in phosphatidylcholine lipid heads, which appear in ample amounts in
mitochondrial membranes (Movasaghi et al., 2007; Alberts et al., 2007; Stone et al.,
2002). This band had a higher intensity in PAD patients compared to control patients and
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may be indicative of higher mitochondrial content. Other PAD biochemical studies have
also reported elevated levels of mitochondrial content and mitochondrial dysfunction that
result in compromised bioenergetics in PAD patients (Pipinos et al., 2008b). However, it
should be noted that phosphatidylcholine is not just present in mitochondria and appears
in many other locations as well. Therefore, the increased intensity in this band may also
indicate possible accumulations of debris or could be due to target lesions which may
have elevated levels of membranes. The 752 cm-1 band was attributed to porphyrin
breathing mode, and is a direct measure of heme groups from hemoglobins providing an
informative status of red blood cells (Movasaghi et al., 2007; Deng et al., 2005). This
band may be reflecting the reduced blood flow in the lower limb musculature caused by
stenosis of the arteries in PAD patients.
Other prominent bands occurring at 1546 cm-1 and 1688 cm-1 were attributed to
the reduced form of nicotinamide adenine dinucleotide (NADH) (Deng, 1989). The
Raman scattering bands occurring at 1032 cm-1 was attributed to the oxidized form of
NAD+ (Yue, 1986). Cellular respiration studies indicate that increased production of
reactive oxygen species (ROS) result in the oxidation of NADH to NAD+ (Zuo and
Clanton, 2005; Sriramoju et al., 2008). NADH is an essential coenzyme, within the
mitochondria, that plays a critical role during the oxidative phosphorylation process.
Based on the Raman spectra (Figure 5.40), controls had higher intensities in NADH
bands (1546 and 1688 cm-1) compared to PAD patients. This suggests that PAD patients
have reduced levels of NADH and increased levels of NAD+. This band could be used as
a Raman spectral biomarker of oxidative stress in PAD muscle tissue.
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Raman scattering band observed at 1602 cm-1 has been associated with human
mitochondria (Huang, 2004; Pully and Otto, 2009). Figure 5.40, shows that PAD
patients have a higher 1602 cm-1 band than control patients and suggests higher
mitochondrial content in PAD patients. Again this is in agreement with other PAD
studies that have demonstrated that PAD patients have significantly increased levels of
mitochondrial content (Pipinos et al., 2008d; Brass and Hiatt, 2000). Although there is an
increase in mitochondrial content in PAD muscle, respiration or oxidative
phosphorylation is still lower when compared to the controls due to mitochondrial
dysfunction (Pipinos et al., 2008d). Mitochondrial dysfunction can produce reactive
oxygen species, which in turn could damage the phospholipid mitochondrial wall.
Although this study presents spectral biomarkers that are in agreement and are
explained by other PAD studies, this study does have limitations. This study was
performed using a small sample set of only 15 patients. The results presented in this
study should be further validated with a larger data set. In addition, the Raman spectral
signal is a complicated mixed biochemical profile that can be hard to interpret.
Researchers have developed Raman spectral libraries of biological tissue to aid in the
interpretation of Raman spectra (Movasaghi et al., 2007). However, the interpretation
should be validated with controlled studies that vary concentration of the molecule and
validate that the spectral peak changes accordingly. Therefore, further biochemical
analysis should be performed to isolate and validate the presence of the suspected
biochemical profile of PAD muscle tissue.
In this study we have demonstrated that Raman spectroscopy can be a powerful
bioanalytical tool that is capable of detecting and correlating biochemical composition
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with patient ABIs and discriminating PAD clinical diagnosis. Raman spectroscopy
provides novel spectral biomarkers the may complement existing diagnosis and treatment
monitoring methods of peripheral arterial disease (PAD). Identification of these spectral
biomarkers may lead to novel disease progression tracking techniques by providing
information that reflects the underlying pathophysiology and allows the development of
individualized therapy. The long-term goal of this research is the quantification of PAD
muscle degeneration progression or regression in vivo and in situ, as that would have the
greatest impact on disease management, facilitating patient specific care.
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Figure 5.38. A) Raman spectra were baseline corrected using a 5th order polynomial
with the Vancouver Raman Algorithm. B) The extracted Raman signal after baseline
correction.

Figure 5.39. Surface-enhanced Raman spectroscopy (SERS) enhances the spectral
signature of myofibers mounted on nanostructured gold-slides when compared to
myofibers mounted on glass slides.
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Figure 5.40. Average control, claudicating, and CLI patient SERS.
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Table 5.7. Demographics of patients with peripheral arterial disease and control patients.
Control

Claudication

CLI

5

5

5

Mean Age (years) ± Std. deviation

63.2 ± 6.02

67.8 ± 9.58

58.4 ± 2.82

Ankle brachial index (ABI)

1.06 ± 0.03

0.55 ± 0.03

0.19 ± 0.06

Number of subjects
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Table 5.8. Patient classification with a discriminant model and cross validation results.
Predicted Membership
Accuracy %

Controls
Actual
Claudication
Membership
CLI
Total

Controls

Claudication

CLI

Total

5

0

0

5

100%

0

5

0

5

100%

0

0

5

5

100%

5

5

10

15

100%
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CHAPTER 6 : SUMMARY AND RECOMMENDATIONS FOR FUTURE
RESEARCH

6.1 SUMMARY
Peripheral arterial disease (PAD) is a vascular disease characterized by stenosis of
the non-coronary arteries caused by fatty deposits and plaque buildup, known as
atherosclerosis (Hirsch et al., 2006). It is estimated that PAD affects approximately 8-10
million Americans and produces a considerable public health burden (Norgren et al.,
2007; Hiatt et al., 1995). PAD is a slowly progressive disease that develops over many
years and becomes more common as one gets older. The number of affected Americans
is expected to increase as the population of elderly persons continues to increase
(Feinglass et al., 1999; Allison et al., 2007). The pathophysiology of PAD is complex and
involves changes occurring on multiple levels, such as reduced blood flow, altered
metabolic processes, and skeletal muscle degeneration. PAD affects a large range of
arterial beds, with most occlusions occurring in the arteries of the legs, pelvis, and
abdominal aorta causing reduced blood flow to the lower extremities. In the past it was
presumed that the manifestations of PAD were solely due to the atherosclerotic blockages
and reduced blood flow to the limbs. However, the end-organ effects, due to PAD, are
more complex than what can be explained by the mismatch of blood flow and oxygen
demand (Hirsch et al., 2006). There is a myopathy that occurs secondary to the vascular
disease producing progressive accumulation of ischemic injury to the lower limbs that is
reflected in a degradation of the lower limb musculature (Pipinos, et al., 2008). The
repeated cycles of ischemia followed by reperfusion trigger inflammatory responses,
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compromise cellular bioenergetics, and generate reactive oxygen species (Pipinos et al.,
2008).
In this dissertation morphometric determinants, biochemical (mechanisms-based
biomarker expressions), and spectral (Raman scattering) parameters of myofibers, in slide
specimens of needle biopsies of the gastrocnemius, were used to characterize PAD
muscle degeneration. This contribution to PAD muscle degeneration research is
significant because it may provide a basis for advances in both therapeutic intervention
and improved monitoring of disease progression and clinical treatment interventions of
PAD.

6.1.1 Objective 1 – Morphometric analysis of PAD muscle
This objective focused on characterizing the histology of PAD muscle with
specific, quantifiable morphometric parameters of PAD and control myofibers. A
discriminant model, based on myofiber morphometrics, was developed and used to grade
myofiber damage in the gastrocnemius of PAD patients. In a small validation data set of
28 patients, the model correctly classified CLI, claudicating, and control patients with
88.8%, 77.7%, and 80.0% accuracies respectively, yielding an overall accuracy of 82.1%.
Among the predictors, for the discriminant model, fiber density, variation of
solidity, and roundness, had the most weight in the discriminant model. Low fiber
density reflects advanced injury characterized by fibrosis and deposition of adipose
tissue. This measurement quantifies the endomysial (in between myofibers) and
perimysial (around myofascicles) thickening that occurs with increasing muscle damage.
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Roundness appears to represent myofiber degeneration and/or necrosis associated with
loss of sarcolemmal integrity and characterized by myofiber swelling.
The discriminant scores, from this model, provided an index of disease severity in
the patient limb musculature. This grading index was a robust first step towards
quantifying the progression of degeneration in the PAD leg. Claudicating patients with
higher discriminant scores had more myofiber damage, similar to that of CLI patients.
The higher the discriminant scores the higher the muscle degeneration. This information
may be used as a marker to identify and stage claudicating patients that may be prone to
deteriorate to CLI. Clinicians may therefore consider more aggressive treatment for these
patients. Claudicating patients with lower discriminant scores had less myofiber damage
and may be considered for different treatment. Similarly, a grading index (coupled to
clinical findings) may help clinicians choose the CLI patients that may be better served
by revascularization, amputation or non-operative management. These findings will help
advance the understanding of how the leg as end-organ is being damaged in PAD and
quantify accurately and in a patient-specific manner the degree and type of degeneration
in the PAD limb.
6.1.2 Objective 2 – Oxidative damage and morphometric analysis of PAD
muscle
The goal of this objective was to quantify oxidatively altered proteins (hydrazidereactive carbonyls) with mechanisms-based molecular biomarkers and mathematically
model disease progression based on a combination of morphometrics and oxidative
damage. PAD produces a progressive accumulation of ischemic injury to the limbs that
is reflected in a gradual worsening in the microscopic morphology and oxidative stress in
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the gastrocnemius (calf muscle). This comprehensive discriminant model incorporated
morphometric parameters of myofibers, oxidative damage in myofibers measured as
protein carbonylation, measures of centrally located nuclei, and measures of clustering
micro-fibers to create an improved discriminant model. Biopsies were collected from the
gastrocnemius with a Bergstom needle from PAD patients with claudication (n=19) and
critical limb ischemia (CLI; n=20) and control patients (n=21). The discriminant model,
based on morphometric and oxidative stress parameters, was able to correctly classify
clinical stages of PAD and control patients with an overall accuracy of 83.3% using a
cross-validation procedure. Myofiber morphometrics plus oxidative stress parameters
provided a discriminant model that establishes a correlation between PAD progression
and advancing muscle degeneration. This model effectively separated PAD and control
patients and provided a grading of muscle degeneration within clinical stages of PAD.
6.1.3 Objective 3 – Raman spectral analysis of PAD muscle
The work has demonstrated that surface enhanced Raman spectroscopy can be a
powerful bioanalytical tool that is capable of detecting and correlating biochemical
composition with patient ABIs and discriminating PAD clinical diagnosis. Raman
spectral biomarkers were identified and may be useful in complementing existing
diagnosis and treatment monitoring methods of peripheral arterial disease (PAD).
Muscle tissue biopsies of the gastrocnemius (calf muscle) were collected from 5 patients
with clinically diagnosed critical limb ischemia (CLI), 5 patients with clinically
diagnosed claudication, and 5 control patients who did not have PAD. A partial least
squares regression (PLSR) model was developed and was able to predict patient ABIs
with a correlation coefficient of 0.99 during training and a correlation coefficient of 0.85
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using a full cross-validation. When using the first three PLS factor scores in combination
with linear discriminant analysis, the discriminant model was able to correctly classify
the control, claudicating, and CLI patients with 100% accuracy, using a full cross
validation procedure. This study demonstrated that Raman spectroscopy can be a
powerful bioanalytical tool that is capable of detecting and correlating biochemical
composition with patient ABIs and discriminating PAD clinical diagnosis. Raman
spectroscopy provides novel spectral biomarkers the may complement existing diagnosis
and treatment monitoring methods of peripheral arterial disease (PAD).

6.2 RECOMMENDATIONS FOR FUTURE RESEARCH
Morphometric parameters, mechanisms-based molecular biomarkers of oxidative
stress, and Raman spectroscopy analyses, of PAD muscle tissue showed promise as
objective measures of muscle degeneration and methods for characterizing biochemical
differences correlating to clinical stages of PAD. Future research should be carried out
with larger data sets to continue to validate and fine tune the models. In addition, further
development of multi-scale comprehensive models incorporating morphometrics,
oxidative stress, Raman spectroscopy, and Fourier transform infrared spectroscopy may
provide a more complete picture that more effectively models the biological phenomena.
Fourier transform infrared spectroscopy (FTIR) is another powerful spectroscopic
tool that is often useful for biochemical analytics. Raman and FTIR spectroscopy both
rely on vibrational energies of molecules for detection, but each method has different
selection rules (Sasic and Ozaki, 2010). In other words, molecules that produce Raman
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spectral peaks generally will not appear in IR spectra and vice versa molecules that
generate IR spectral peaks will not appear in Raman spectra. These selection rules are
useful because they make the two spectroscopic methods complementary to each other.
Because FTIR and Raman spectroscopy are complementary the combination of these
methods may provide a more complete biochemical profile of PAD muscle. It would be
very useful to combine these two complimentary techniques to further characterize
biochemical alterations in PAD muscle tissue.
Time resolved Raman spectroscopy may also prove to be a very useful analysis.
Time series Raman spectra of freshly harvested muscle tissue incubated in an oxygen
controlled chamber that cycles oxygen concentrations from resting to ischemic
conditions, to simulate oxygen supply and demand in that occur in the body, may be very
useful to examine in real time which Raman bands change shape.
Raman spectroscopy can be further advantageous when it is coupled with imaging
(i.e. mapping), which renders information rich Raman hyperspectral images. Raman
mapping is capable of identifying and constructing chemical maps of subcellular
structures such as, the nucleus, cytoplasm, and mitochondria (Miljković et al., 2010;
Bonnier et al., 2010). Therefore, Raman spectral imaging (mapping) may be useful in
providing insight into the biochemical spatial distribution of PAD myofibers and provide
a visual of the biochemistry of PAD myofibers with respect to their neighboring
myofibers. Therefore, I recommend as a future aim to collect Raman spectral maps of
PAD and control myofibers and evaluate the biochemical spatial distribution. The
successful completion of this future work may offer valuable insight as to where
pathological changes occur within the muscle fibers. This may be very useful to identify
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group atrophy and provide insight as to how these pathological changes spread and affect
neighboring muscle fibers. For example, if a target legion is located and a cluster of
fibers within a local neighborhood begin to become atrophic, these techniques may be
able to examine biochemical changes occurring in the neighboring healthy muscle fibers.
With high spatial and spectral resolution Raman mapping may prove to be a powerful
technique for monitoring cellular physiology on a molecular level.
As a long term goal I suggest the development of a Raman spectral probe that
may be used minimally invasively. A minimally invasive Raman spectral probe may
useful in the detection of PAD muscle degeneration progression or regression in vivo and
in situ, and may provide a great impact on disease management. A minimally invasive
Raman probe may be able to provide real time monitoring of muscle biochemistry during
revascularization procedures or may be used to monitor progression or regression of
PAD.
Further, the myofiber morphometric discriminant model showed promise in
providing a grading index, to grade disease severity; however, one of the downfalls in
this model is that it requires a biopsy from the patient. The biopsy is minimally invasive;
anytime we can get away from invasive procedures and in turn perform a noninvasive
analysis the better. Therefore, my suggestion is to further evaluate the potential of
noninvasive imaging modalities that may be capable of capturing myofiber morphology
in a noninvasive manner. Noninvasive imaging techniques that can capture myofiber
morphology offer the potential to improve patient specific diagnosis and improve
treatment monitoring.
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Among the potential imaging modalities that may be capable of measuring
myofiber morphology in a noninvasive manner are micro-ultrasound and MRI. A
literature review article on ultrasound imaging and muscle limb function indicate that
ultrasound imaging is capable of assessing components of muscle morphology (Walker et
al., 2004). However, ultrasound images are very noisy and at times may be hard to
interpret. Moreover, it may not be possible to image cross-sectional views of individual
myofibers, although there are some literature reports that indicate high resolution microultrasound is able to resolve the micro-anatomy of myofibers (Walker et al., 2004; Van et
al., 2009). Despite these potential limitations, ultrasound may still be useful in collecting
information that can be correlated to muscle damage.
Physiological studies of patients with PAD indicate that there is a myopathy with
mitochondrial dysfunction and oxidative damage to the muscle. In addition to using
protein carbonylation biomarkers, to measure oxidative stress, PAD injury could be more
precisely quantified by incorporating more biomarkers. Therefore, future research could
also incorporate other biomarkers such as, 4-hydroxy-2-nonenal (HNE), which is
produced during lipid peroxidation and appears in higher quantities during oxidative
stress, ATP-synthase to measure for active mitochondria, ‘phosphatase and tensin
homolog’ (PTEN) induced putative kinase 1 (PINK1) to stain for depolarized
mitochondria, and signaling adaptor p62 to stain for ubiquitininated proteins that are
marked for destruction.
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CHAPTER 7 : APPENDICES:
7.1 EXAMPLE MYOSIN AND SARCOLEMMA LABELING PROTOCOL USED
IN CHAPTER 3
Objective: Label myofiber myosin and sarcolemma for morphometric analysis of PAD
and control gastrocnemius biopsies
Rationale: Preliminary work suggests that morphologic features of PAD myofibers may
discriminate PAD and control specimens, and may correlate with disease severity.
Design:












Slide specimens: 4 u sections of gastrocnemius biopsies from PAD patients and
controls
o Controls: 4 patients; H170, H171, H174 and H176
o Claudicating patients: 4 patients; H168, H169, H175 and H180
o Critical ischemia patients: 4 patients; H130, H135, H137 and H173
Deparaffinize slides with xylene
Hydrate slides to distilled water
Transfer slides to pre-heated epitope recovery solution
Set Pap pen windows
Apply goat serum
Incubate slides with a mixture of anti-Myosin I&II Abs (1hr)
Treat slides with Alexa Fluor 488 goat anti-mouse IgG (1hr)
Apply wheat germ agglutinin Alexa Fluor 350 (1hr)
Mount specimens in ProLong Gold and observe specimens with the Leica microscope

Materials:




Slide specimens
o Gastrocnemius biopsies
o Specimens fixed in methacarn for 48 hours at 4o C
o Transferred to 50% EtOH at 4o C
o Paraffin embedded and sectioned at 4 u
AlexaFluor 350 conjugate wheat germ agglutinin, 1mg/ml: Molecular Probes
cat # W11263, lot # 510811
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Anti-Type ‘1’ fiber: mouse monoclonal antibody; Sigma cat. # M8421, lot #
115K4768, clone # NOQ7.5.4D; ascites fluid w/ 7.5 mg IgG/mL
Anti-Type ‘2 fiber: mouse monoclonal antibody; Sigma cat. # M4276, lot #
026K4854, clone # MY-32; 7.8 mg IgG/ml
Alexa Fluor 488 conjugated goat anti-mouse IgG, 2mg/ml; Molecular Probes cat. #
A11004, lot # 745480
Antibody diluent: Zymed cat. # 00-3218, lot # 546892A, exp. 07-2010
Goat serum, 10%: Zymed cat. # 50-062Z, lot # 463107A, exp. 12-2009
Super Sensitive Wash Buffer: BioGenex HK583-5K, lot # HK5831208B
Tris: Invitrogen 15504-020, lot # 1140381
Dipotassium EDTA: Sigma ED2P, lot # 050K0247
Tween 20, Sigma cat. # P-7949, lot # 092K0051
Phosphate Buffered Saline, Invitrogen cat. # 14190, lot # 478900
Xylenes, Fisher cat. # X5P-1GAL, lot # 064546
Absolute EtOH, AAPER lot # 06H17WA
95% EtOH, General Supply, cat. # CP-3537
Methanol, EMD cat. # MX0475-1, lot # 43184328
Chloroform
Acetic acid, Fisher cat. # A38-212, lot # 053916
Hydrochloric Acid: Acros 423795000, lot # A0208645001

Procedures:
Prepare Tris buffer for epitope recovery
 Tris base
 Dipotassium EDTA
 DdH2O
 Adjust to pH 9.0
 Tween 20
Deparaffinize and hydrate sections

1.45 g
0.44 g
1200 mL
600 uL

 Xylene, change ‘1’: 5 minutes w/ agitation
 Xylene, change ‘2’: 5 minutes w/ agitation
 Abs EtOH, change ‘1’: 3 minutes w/ agitation
 Abs EtOH, change ‘2’: 3 minutes w/ agitation
 95% EtOH: 1 minute w/ agitation
 80% EtOH: 1 minute w/ agitation
 DdH2O: 1 minute w/ agitation
Epitope recovery





Transfer the slide to Tris buffer at 94o C
Keep at 94o to 98o C for 30 minutes
Allow the Tris with slides to cool on the bench for 20 minutes
Transfer the slides to Super Sensitive Wash Buffer at room temp for 30 minutes with
a stir bar (setting of 2)
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Place a lipid frame on each slide







Tap off water
Dry glass, except for tissue area
Add a drop of buffer to tissue sections (keep wet)
Draw frame to include middle 1/3 of slide
Add buffer to the tissue sections
Transfer slides to the BioGenex slide rack

Prepare the anti-Type I Myosin (10.0 ug/ml) plus anti-Type II Myosin (10.4 ug/ml)
mixture
 9000 ul of antibody diluent (50 cc conical tube)
 12 ul of anti-Type I Myosin
 12 uL of anti-Type II
Prepare Agglutinin (10 ug/mL) plus secondary antibody (20 ug/mL) mixture





8000 uL of antibody diluent (50 cc conical)
Centrifuge the wheat germ agglutinin solution (100 uL) and Alexa 488 goat antiMIgG (100 uL) in the Fisher Microfuge at a setting of ‘10’ for 4 minute, room temp
Collect 80 ul of each supernatant
Dilute supernatants up to 8000 uL (antibody diluent)

Run the AutoStainer program



Bring all solutions to room temperature
Bring the slides to room temperature

Program the AutoStainer for the HNE/Carbonyl Slides










Prewash
Buffer
Buffer
10% goat serum
Anti-myosin mix
Buffer
WGA/Anti-M IgG mix
Buffer

Duration

Repeats

Final rinses

4 min
4 min
20 min
1.5 hour
4 min
1.0 hour
4 min

5
3
0
0
2
0
2

2
2
1
2
2
2
2
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Options:




Target middle 1/3 of each slide
Deliver 250 uL reagent
Inactivate the level sensor of the pipetting system

Cover the tissue sections with ProLong Gold antifade medium



Avoid bubbles
Store slides at 5o C

180

7.2 EXAMPLE PROTEIN CARBONLY LABELING PROTOCOL USED IN
CHAPTER 4.
Objective: Evaluate the morphometric and carbonyl content of the PAD and control
muscle and attempt to decrease the signal with borohydride reduction.
Rationale: Oxidative stress results in the formation of protein carbonyls. We will
evaluate the PAD and control oxidative stress by biotin hydrazide labeling of carbonyl
content.
Design:


Three slides per subject
o A (Negative (-) Myosin & Negative (-) Carbonyl)
o B (Positive (+) Myosin & (+) Carbonyl)
o C (Positive (+) Myosin & (+) Carbonyl)
 Slide specimens prepared: (total 12 humans)
o Control Patient: H217; H52;H51
o PAD -Moderate: H215; H108;
o PAD- Severe: H229; H162; H139; H178; H185; H186; H184; H108;
o Carry Through: Control (H217) and MOD (H215) and SEV (H229)
(Day 1)
 Deparaffinize slides with xylene
 Hydrate slides to distilled water
 Transfer slides to Citrate pH 6.0 solution for epitope recovery
 Heat the slides at the microwave at 65°C for 10 min
 Cool slides and transfer to supersensitive wash buffer
 Set Pap pen windows
 Extensive washing of the slides
 Perform avidin/biotin block
 Perform biotinylation
 Stabilize hydrazine bonds with cyanoborohydride
 Store with PBS on tissues in hydration chamber in refrigerator
(Day 2)








Label with Streptavidin-AlexaFluor 488 (Carbonyl Labeling)
Wash the slides and apply goat serum block (Blocks non-specific binding sites)
Label (primary) with myosin mixture Anti-Type I/II Myosin
Label negative slides with Mouse IgG (Isotype Control)
Label (secondary) Alexa 594 Goat Anti-Mouse IgG (Myosin Labeling)
Label AlexaFluor 647 conjugate wheat germ agglutinin (Sarcolemma Labeling)
Mount specimens in ProLong Gold (with DAPI) and observe specimens with the
Leica microscope
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Materials:


Slide specimens
o Gastroc
o Specimen fixed in methacarn for 48 hours at 4o C
o Transferred to 50% EtOH at 4o C
 Avidin/Biotin Blocking Kit, Zymed ref. # 00-4303, lot # 911665A rec.06/21/11
exp.8/12
 Biotin Hydrazide: CALBIOCHEM, cat# 203110, lot# D00092953, rec. 8/27/11, exp.
NA, MW: 484.66
 Streptavidin-AlexaFluor 488: Molecular Probes S32354, lot # 748200 (2 mg/mL) rec.
6-24-11 exp. N/A
 10% Normal Goat Serum, Invitrogen lot# 899064A, ref# 50062Z, rec 02/22/11,
opened 04/08/11
 Anti-Type ‘1’ fiber: mouse monoclonal anti-myosin (skeletal, slow); Sigma cat. #
M8421-.2ML, lot # 011M4813, clone # NOQ7.5.4D; ascites fluid w/ (9.4 mg
IgG/mL)
 Anti-Type ‘2 fiber: mouse monoclonal anti-myosin (skeletal, fast); Sigma cat. #
M4276-.2ML, lot # 059K4787, clone # MY-32; (8.5 mg IgG/ml)
 Mouse IgG, Vector Laboratories Inc., lot#W0301, (2000 mg/1000mL), rec 07-06-10.
 Alexa Fluor 594, goat anti-mouse IgG (H+L), Invitrogen Molecular Probes A11032,
lot# 870954, (2mg/mL) rec. 6-24-11 exp. N/A
 Alexa Fluor 647 conjugate wheat germ agglutinin, (1mg/ml): Molecular Probes
cat # W11263, lot # 880275 rec. 2/22/11 exp. 9/11
 Prolong Gold antifade reagent with DAPI, Invitrogen, P36931, lot # 838018 rec. 2/11
exp. N/A
 Antibody diluent: Invitrogen cat. # 00-3258, lot # 813641A, rec. 12/1/10 exp. 12/11
 Super Sensitive Wash Buffer: BioGenex HK583-5K, lot # HK5830311 rec.6/21/11
exp. 03/13
 2-Morpholinoethane sulfonic acid (MES): Sigma, M3671-250G, lot # 020M5421 rec.
8/25/10 exp. N/A, FW: 195.20
 Phosphate Buffered Saline (PBS): (made in lab)
 Ethylenedieminetraacetic acid (EDTA): Invitrogen, ED2P, lot# 050K0247
 Tween 20, Sigma cat. # P-7949, lot # 109K01021 rec. 3/1/10 exp. N/A
 Xylenes, Fisher cat. # X5P-1GAL, lot # 084827
 Absolute EtOH, AAPER lot # 06H17WA
 95% EtOH, General Supply, cat. # CP-3537
 Sodium Cyanoborohydride, 95%; Aldrich cat. # 156159-10G, lot # rec. 23/2/11 MW:
62.84
 Sodium Chloride, Fisher cat. # S271-1 rec. 06/05 exp. N/A MW: 58.44
 Sodium Hydroxide, Fischer cat. # S318-500, lot # 034906 rec. 10/3 exp. N/A MW:
40.00
 Hydrochloric Acid: Acros 423795000, lot # A0208645001
 Dimethylsulfoxide (DMSO), Sigma; cat. # 8418-250ML; lot # 845961MV rec.
02/23/11 exp. N/A
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Procedures:
Day 1
1.







2.




3.







Prepare Citrate buffer for epitope recovery
29.4 g
Tri-sodium citrate dihydrate
1000 mL
DdH2O
Adjust pH to 6.0
500 uL
Tween 20

Comments:

Store in refrigerator

Prepare MES Buffer (Biotinylation Buffer)
200 mL
3.99 g MES to 200 mL DDW
Adjust the pH to 5.5, with concentrated NaOH

Comments:
Solution is good for 1 week
Sample Calc: If we wanted to just prep.
50ml

Prepare 0.01 M Na Phosphate w/ 0.85% NaCl (PBS)
DdH20
1000mL
Na2HPO2
0.719 g
NaCl
4.2 g
Na2HPO4
0.69 g
NaCl
4.2 g

Comments:
(Makes 1 Liter)
Fill 2 large beakers with 500 mL DdH20
Add .719 g Dibasic & 4.2 g NaCl to 1
beaker, Add 0.69 g Monobsic & 4.2 g NaCl
to the other

To 400mL Dibasic, add Monobasic to pH 7.2

4.




Prepare Super Sensitive Wash Buffer
DdH2O
1900 mL
SS Buffer
100 mL

Comments:
(Makes 2 Liters)

Deparaffinize and hydrate sections








Xylene, change ‘1’: 5 minutes w/ agitation
Xylene, change ‘2’: 5 minutes w/ agitation
Abs EtOH, change ‘1’: 3 minutes w/ agitation
Abs EtOH, change ‘2’: 3 minutes w/ agitation
95% EtOH: 1 minute w/ agitation
80% EtOH: 1 minute w/ agitation
DdH2O: 1 minute w/ agitation

Epitope recovery


Transfer the slides to citrate buffer in the container of the microwave
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Set microwave to 65°C for 10 min
Allow solution with slides to cool in the fume hood for 20 minutes
Transfer the slides to Super Sensitive Wash Buffer at room temp with a stir bar
(setting of 2) for 30 minutes

Place a lipid frame on each slide







Tap off buffer
Dry glass, except for tissue area
Add a drop of buffer to tissue sections (keep wet)
Draw frame to include middle 1/3 of slide
Add SS buffer to the tissue sections to keep hydrated
Transfer slides to the BioGenex slide rack

Program & Run the AutoStainer
Duration










Prewash
Buffer
Buffer
Avidin
Buffer
Biotin
Buffer
MES

4 min
4 min
10 min
4 min
10 min
4 min
5 min

Repeats

Final rinses

5
3
0
2
0
2
0

2
2
2
2
2
2
0

Comments
(Super Sensitive Buffer)
(Super Sensitive Buffer)
(Bind to native biotin)
(S.S. Buffer)
(Binds to 4 sites in Avidin)
(S.S. Buffer)
(Biotinylation Buffer)

Options:




Target middle 1/3 of each slide
Deliver 250 uL reagent (if 2/3 of slide increase to 500 uL)
Inactivate the level sensor of the pipetting system

Prepare Biotinylation Solution
(Step1)

(Step2)
Prepare
Immediately
prior to use

Prepare 50 mM Biotin Hydrazide
DMSO Solution
 DMSO (on shelf)
 Biotin Hydrazide (in
refrigerator)

Comments:
100 ul
2.5 mg

Prepare 5 µM Biotinylation
Solution




50 mM Biotin DMSO
(from step1)
MES Buffer

(get two vials 1st dissolve Biotin
in DMSO then add that solution
to MES if crystals form
―sonicate.
(reacts with aldehydes &
keytones & forms hydrozone
bonds)

100 ul
900 ul

(stirred in warm water)
(Yields 1 mL)

184

Biotinylation




Add 400 ul of Biotinylation solution to each slide
Incubate at room temperature for 1 hr in flat black slide box (fill bottom of box
with plenty of DdH2O)
Wash slides with PBS in glass container with stir bar (setting 2) for 10 min.

Prepare 15 mM Cyanoborohydride
Comments:




PBS (in refrigerator)
Sodium cyanoborohydride
(in vacuum under the hood)

250 ml
0.24 g

(Mix under the Hood)
(Yields 1 glass containers worth)

Stabilize the hydrazone bonds with cyanoborohydride




Tap off the biotinylation solution
Place slides in 250 ul of 15 mM cyanoborohydride in glass container
Incubate at room temperature with stir bar (setting 2) for 30 minutes

Prepare for overnight incubation





Fill flat black slide boxes with DdH20 (enough to fully coat the bottom)
Dip each slide in PBS several times to wash
Place slides in slide box and flood windows with PBS
Store overnight in refrigerator
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Day 2 Procedures:
Prepare the Streptavidin-Alexa 488 (10 ug/ml):




Centrifuge the streptavidin in the Fisher Microfuge at a setting of ‘10’ for 4 minute
17.5 ul of Streptavidin (put back in refrigerator when done)
3500 uL Ab Diluent (1:200)

Prepare the mixture Anti-Type I/II Myosin (10 ug/ml)




2000 uL of antibody diluent
2.5 uL of Anti-Type I (slow) Myosin (1:940)
2.5 uL of Anti-Type II (fast) Myosin (1:850)

Prepare the Mouse IgG (Isotype Control) (5 ug/ml):




Centrifuge the mouse IgG in the Fisher Microfuge at a setting of ‘10’ for 4 minutes
2 uL of Mouse IgG
5000 uL Ab Diluent (1:400)

Prepare the Alexa 594 Goat Anti-Mouse IgG (10 ug/ml):




Centrifuge the Alexa fluor in the Fisher Microfuge at a setting of ‘10’ for 4 minute
20 uL of Alexa 594
4000 uL Ab Diluent (1:200)

Prepare Agglutinin Alexa 647 (1:100)





Centrifuge the wheat germ agglutinin solution in the Fisher Microfuge at a setting of
‘10’ for 4 minute
Add 50 uL of the supernatant
2500 uL of Ab Diluent (1:50)
Notes: Vortex wheat germ agglutinin rigorous 3 times before use
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AutoStainer
Program the AutoStainer














Pre-wash
Buffer
Streptavidin 488
Buffer
Goat Serum
Myosin Mixture
Isotype Control
Buffer
Alexa 594
Buffer
Agglutinin
Buffer

Duration

Repeats

Final rinses

4 min
30 min
4 min
20 min
90 min
90 min
4 min
30 min
4 min
60 min
4 min

2
0
2
0
0
0
2
0
2
0
2

2
0
2
1
0
0
2
0
2
0
2

Options:




Target middle 1/3 of slides
Deliver 250 uL reagent per slide
Inactivate the level sensor of the pipetting system

Runs the autostainer
Mount the slides with ProLong Gold Anti-fade medium with DAPI


30 uL for each slide

Store at room temp in slide folder

Observe the slide specimens with the Leica system

